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7 
There is an increasing evidence that microRNAs are involved in control of 
developmental timing, cell proliferation, apoptosis, morphogenesis, fat metabolism. In 
many studies, performed to investigate the genes and gene products that drive the 
metastatic process, it has become evident that, in addition to alterations in protein-
encoding genes, abnormalities in non-coding genes can also contribute to cancer 
pathogenesis. Changes in miRNA levels may be related to dysregulated growth in 
some cancer cells and in this field the differential expression of miRNA may have 
substantial diagnostic and prognostic value. In the context of microRNAs in tumours, 
our aim was to evaluate whether pro-metastatic and non-metastatic sarcoma cells, may 
differ in their microRNA expression, in the effort to identify single pro-metastatic 
microRNAs in bone and soft-tissue sarcomas. microRNAs were separated from total 
RNA of MG-63 and 143B osteosarcoma cells with different intravasation behaviour and 
malignancy degree. Specific libraries were constructed using TopoTA cloning system 
supported by 5’- and 3’ adaptors. Differentially expressed microRNA were identified by 
sequencing followed by bioinformatic analysis. A number of microRNAs reported in the 
data base miRNA registry were found to be differential expressed in the two 
osteosarcoma model cell lines. Of the over 19 microRNAs identified, the majority 
correspond to “oncomiR”, i.e. microRNAs involved in neoplastic transformation and 
progression. One of the analysed sequences, localized on chromosome 7 of the 
human genome, showed miRNA configuration and studies are in progress to define its 
precise characteristics. Two of the differential expressed microRNA, miR-93 and miR-
210, for which no functional data were available, were analyzed in different cell lines 
and tissues and investigated for their potential involvement in motility phenomena by 
their mis-expression through transduction in to osteosarcoma cells. To identify their 
molecular targets, different approaches were performed using bioinformatic softwares, 
through PCR-based strategies and DNA microarray analyses. The expression of 
another set of four miRNAs (miR-9, miR-183, miR-196a, miR-484) differentially 
expressed, was identified through a global expression analysis, and analyzed in 
surgical specimens of low- and high-grade osteosarcoma patients. To better define the 
significance of the expression pattern of these microRNAs, studies on a wider patient 
cohort are in progress. 
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1.1 The spreading of neoplastic cells 
Tumour cell dissemination and subsequent metastasis formation in adjacent 
tissues/organs or in anatomical sites distant from the primary lesions are the prevalent 
cause of death in cancer patients (Kurschat and Mauch, 2000; Liotta and Stetler-
Stevenson, 1991; Pepper et al., 2003; Stacker et al., 2002). 
The basis for neoplastic cell diffusion is their entrance into haematic and 
lymphatic vessels, either situated in proximity of the tumour mass or newly generated 
within it, and subsequent malignant cell transportation trough these streams. Although 
information has constantly been gathered about the cellular and molecular 
mechanisms underlying the tropism of various tumour cells for different organs or 
tissue (bone and lymph nodes being the overwhelmingly most frequent one), we are 
still rather ignorant about how cancer cells actually decide to stop and extravasate (i.e. 
egress to the circulation) in pre-selected organ or tissue location. 
The importance of many cell surface molecules in the phenomenon of 
extravasation is still not fully understood (Figura 1.1), neither the relationships among 
these various components. Selectins (Geng et al., 2004) and their oligosaccharide 
ligands, various class of integrins and their cell surface-associated molecules (i.e. 
ICAM1-3 and LFA1-3), integrin-interacting/cooperating surface components (e.g. 
members of the tetraspan family), various types of surface glycolipids, gangliosides 
and mucins and metalloproteinase and their inhibitors (Dong et al., 2002) are reported 
as cell surface elements implicated in tumour transendothelial migration. Several cell 
adhesion molecules have been considered as both investigative targets for prognosis 
and diagnosis determination of specific tumour types and exploitable therapeutic 
targets. 
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Figure 1.2 Metastatic spreading from primary tumour site 
 
This figure illustrates many aspects of cancer progression where chemokines/receptors 
may play a role: growth of the primary tumour, angiogenesis (cell migration of endothelial 
precursors), metastasis, and survival/growth of the metastasized cells, probably the least 
efficient step in the metastatic process. In the primary lesion, tumour cells (dark blue) are 
supported by a network of cells in the microenviroment including fibroblasts (light blue), 
Dendritic Cells (green) and Tumour Associated Macrophages (yellow). Chemokines, 
produced by the tumour cells, serve to recruit endothelial cells, thereby promoting 
angiogenesis. They also recruit leucocytes, which produce other cytokines, growth factors 
and metalloproteinasis that enhance growth, proliferation and angiogenesis. Fibroblasts 
also produce angiogenic and survival/growth-promoting chemokines. Tumour metastasis 
is facilitated by the up-regulation of particular chemokine receptors (such as CXCR4) on 
the tumour cells, which enables them to migrate to secondary tissues where the ligands 
are expressed. Similar to the primary site, paracrine and autocrine chemokine/cytokine 
signalling among cells within the microenvironment may be especially important for 
survival and growth of the metastasized cells (O'Hayre et al., 2008). 
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1.2 Osteosarcomas 
Sarcomas, whose origin is believed to be associated with both hard and soft 
connective tissue, account for almost 5% of the total malignancies. The predominant 
class is represented by soft-tissue sarcomas (Registry, 2007; Ries, 1999). Comparison 
of the incidence rate shows that osseous neoplasms occur at a rate approximately one 
fifth of that of the closely related group of soft-tissue sarcomas (Dorfman and Czerniak, 
1995; Higginson et al., 1992; Mack, 1995). Osteosarcoma is the most common primary 
malignant tumour of bone, accounting for approximately 35% of these tumours and 
occurs predominantly in patients younger than twenty years of age (Ries, 1999). This 
sarcoma type appears in different anatomical sites, mostly in the extremity, and the 
characteristic metastasis areas are lungs and other skeleton parts.  
The genetic alterations playing an important role in triggering the osteosarcoma 
neoplasm seem to be mutations of tumour suppressor genes. For example, the 
deletion of retinoblastoma gene (RB) on chromosome 13q14 has been found in 60% of 
osteosarcoma patients. However, this tumour is not linked to a specific alteration since 
a lot of karyotypes show different chromosomal amplification (Man et al., 2004). Till 
today, only the histotype analysis is used to identify the various subtypes and establish 
the tumour stage. 
 
Low grade osteosarcomas- In almost 80% of the cases, they are located in the 
long bones with peculiarity for the distal femur and proximal tibia (Kurt et al., 1990). 
They are generally classified in different sub-types the most frequent of which are 
afterwards briefly described. 
Low grade central osteosarcoma (Figure 1.2A) is composed of a hypo- to 
moderately fibroblastic cellular stroma with variable amounts of osteoid production 
(Franceschina et al., 1997);  
Parosteal osteosarcoma (Figure 1.2B.) is the most common type of 
osteosarcoma of bone surface (Okada et al., 1994) and has the tendency to wrap 
around the involved bone (Bertoni et al., 1985); 
Periosteal osteosarcoma (Figure 1.2C) that arises on the surface of a bone, 
displays non-homogeneous, calcified spiculation that are disposed perpendicularly to 
the cortex and give an overall sunburst appearance. It has a conspicuous fusiform 
appearance when it involves the entire circumference of the shaft of a bone (Unni et 
al., 1976). Histologically, periosteal osteosarcoma has the appearance of a moderately 
differentiated chondroblastic osteosarcoma (Unni et al., 1976). 
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Figure 1.1  Low grade osteoarcoma 
 
A. Low grade central osteosarcoma. At low magnification, long, parallel seams of bone 
surrounded by hypocellular spindle cell stroma are seen (Inwards and Unni, 1995). B. 
Parosteal osteosarcoma. Well-formed bone trabeculae in a hypocellular spindle cell 
stroma. (Unni, 1996). C. Periosteal osteosarcoma. Typical appearance of 
chondroblastic grade 3 sarcoma. There are lobules of malignant –appearing cartilage with 
bone formation in the centre of the lobules (Unni et al., 1976).  
 
High grade osteosarcomas – The term “high” is mainly referred to the grade of 
malignancy. The most recurrent types are then in brief described. 
Classic osteosarcoma (Figure 1.3A) shows a profound propensity for 
involvement of the long bones of the appendicular skeleton; in particular, the distal 
femur, proximal tibia and proximal humerus. It is often a large, metaphyseally centered, 
fleshy or hard tumour which may contain cartilage and it frequently transgresses the 
cortex; it is associated with a soft tissue mass. It tends to be a highly anaplastic, 
pleomorphic tumour in which the tumour cells may be epithelioid, plasmacytoid, 
fusiform, ovoid, small round cells, clear cells, mono- or multinucleated giant cells, or 
spindle cells. Most cases are complex mixtures of two or more of these cell types 
(Campanacci, 1990). 
High grade surface osteosarcoma (Figure 1.3B) comprises less than one 
percent of all osteosarcomas. The tumour radiographically presents as a surface, 
partially mineralised, mass extending into the soft tissue; the histopathology shows the 
same spectrum of features seen in classic osteosarcoma (Wold et al., 1990). 
Telangiectatic osteosarcoma (Figure 1.3C) occurs in most cases in the 
metaphyseal region of long tubular bones. The tumour contains blood-filled or empty 
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spaces separated by thin septa simulating aneurismal bone cyst. The tumour cells are 
hyperchromatic and pleomorphic with high mitotic activity including atypical mitoses. 
This tumour tends to make osteoid matrix when it metastasized (Matsuno et al., 1976). 
Small cell osteosarcoma (Figure 1.3D) is composed of small cells associated 
with osteoid production; the matrix shows flocculent dense material in close apposition 
to tumour cell membrane with subplasmalemmal densities in the adjacent cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  High grade Osteosarcoma 
 
A. Classic osteosarcoma. Frequently occurring angiocentric pattern of growth may 
impart a basket-weave appearance while combined with abundant osteoid production 
(Raymond et al., 1987). B. High grade surface osteoarcoma. The tumour produces 
large amounts of bone (right). The cortex (middle) and the medullary cavity (left) are 
uninvolved. (Wold et al., 1990). C. Telangiectatic osteosarcoma. Highly malignant 
tumour cells produce minimal amounts of fine, lace-like osteoid. (Matsuno et al., 1976). D. 
Small cell osteosarcoma. Osteoid production at lower right (Fletcher et al., 2002). 
 
1.3 Biomarkers in human cancer 
A tumour marker can be detected in the tumour lesion, in tumour cells in 
circulating peripheral blood, in metastasis formation or in the body fluids. Markers may 
also be used to detect the presence of occult metastatic disease, to monitor response 
to treatment or to detect recurrent disease (Lindblom and Liljegren, 2000). 
Oncofetal antigens, which are normally expressed in cells during embryological 
development, can be considered in several cases as tumour markers when abnormally 
expressed in neoplasms and result very useful to control the state of patient health. In 
particular, carciembryonic antigen, the most commonly oncofetal antigen, is expressed 
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in all gastrointestinal tumours as well as in many other tumours (Hunerbein, 1998). The 
α fetoprotein, mainly used in the diagnosis of hepatocellular cancer, is also expressed 
in testicular and ovarian cancer (Lamerz, 1997). 
The best-characterized markers are described for the most frequent cancer 
types such as breast, colorectal carcinoma and lung for which genetic alterations and 
serum analyses are routinely carried out. In sarcomas, important markers are those 
associated with chromosomal translocation and fusion proteins. The identification of 
several specific fusion products in very infrequent sarcoma types has allowed for a 
diagnostic improvement. In fact clinical pathological diagnosis is often difficult, while the 
demonstration of a specific fusion protein is diagnostic for these rare sarcomas 
(Lindblom and Liljegren, 2000). 
However, when the application of some clinical markers is limited by their 
apparent lack of specificity or sensitivity, additional biomarkers are required to 
implement a tailored individualized therapy. Many studies are currently conducted with 
this perspective and in the last years the increasing importance of small non-coding 
RNAs in gene regulatory networks has address many researches to unravel their roles 
in cellular processes and to understand their potential as new and additional markers in 
tumours of different kind.  
 
1.4 The small non-coding RNA world 
Four types of gene silencing-related small RNA have been found in animals 
over the past few years: small interfering RNAs (siRNAs), microRNAs (miRNAs), and, 
more recently, repeated associated small Interfering RNAs (rasiRNA) and Piwi-
interacting RNAs (piRNAs) (Kloosterman and Plasterk, 2006). 
siRNAs, also found in plants and yeast, are usually derived from double-
stranded RNA which originates from virus. Generally, siRNAs trigger mRNA 
degradation by binding their targets with perfect complementarity (Meister and Tuschl, 
2004). 
Genomic repeats and retrotrasposons give rise to rasiRNAs. They seem to 
function through a distinct small RNA pathway involving Piwi proteins in Drosophila 
(Saito et al., 2006; Vagin et al., 2006). 
A germline-specific class of vertebrate small RNAs is formed by piRNA, 29-
30nt-long RNAs that act by binding to Piwi proteins. piRNAs are not associated with 
repeats, even if the encoding genes are localized in clusters in the genome (Girard et 
al., 2006). 
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miRNAs are a well established class of ~22 nt endogenous, noncoding small 
RNAs that influence mRNA stability and translation. Although the first miRNA, lin-4, 
was found in 1993 (Lee et al., 1993; Wightman et al., 1993), the miRNA field did not 
take off until the discovery of the highly conserved let-7 small RNA (Reinhart et al., 
2000). 
Since then, several research groups have applied small-RNA-cloning strategies 
to identify new small RNAs in vertebrates and invertebrates (Lagos-Quintana et al., 
2001; Lau et al., 2001; Lee and Ambros, 2001). More recently, hundreds of miRNAs 
have been found in many animal species by in silico analysis, experimental 
approaches, or combined strategies (Berezikov et al., 2006). 
 
1.4.1 Origin and maturation of microRNA 
miRNA genes are transcribed by RNA polymerase II as capped and 
polyadenylated primary miRNA transcripts (pri-miRNA) (Cai et al., 2004; Lee et al., 
2004). The RNAse III enzyme Drosha initiates the nuclear processing of the pri-miRNA 
into an ~70nt precursor miRNA, pre-miRNA (Lee et al., 2003). The double-stranded 
RNA binding protein DGCR/Pasha interacts with Drosha to form the microprocessor 
complex (Kim, 2005). Pre-miRNAs are exported from the nucleus by binding to the 
nucleocytoplasmic transport factor Exportin 5 (Kim, 2004). Maturation of the pre-
miRNA into an imperfect RNA duplex, with 2nt 3’ overhangs, is mediated by the 
cytoplasmic enzyme Dicer (Hammond, 2005). The strand of the duplex with the 
weakest base pairing at its 5’ terminus is preferably loaded into the RNA-induced 
silencing complex (RISC) (Hutvagner, 2005). The miRNA guides the RISC complex to 
the 3’UTR of target mRNAs (Figure 1.3). Animal miRNAs usually pair with imperfect 
complementarity to their target. The seed region (nucleotide 2-8) of miRNAs guide 
strand is the most important for target recognition and silencing (Doench and Sharp, 
2004; Lewis et al., 2005). However, other studies report that miRNA targeting is also 
influenced by additional factors such as the presence of miRNA-recognition elements 
(MREs) and their cooperation (Doench et al., 2003), the spacing among MREs 
(Saetrom et al., 2007), the proximity to the stop codon, the position within the 3’UTR, 
the AU composition (Farh et al., 2005) and the secondary structure of mRNA target 
(Long et al., 2007). The association of miRNAs with their mRNA targets inhibits 
translation. Both the initiation and elongation steps of translation are hypothesized to 
be affected even if the exact mechanism of the process remains unclear (Petersen et 
al., 2006; Pillai, 2005; Valencia-Sanchez et al., 2006). Moreover, repressed mRNAs 
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are present in cytoplasmic foci called P-bodies known as sites for mRNA 
destabilization (Bruno and Wilkinson, 2006). Recent data suggest that, indeed, miRNA-
mediated repression might alter the levels of target mRNA, mainly via mRNA de-
adenylation (Bagga et al., 2005; Giraldez et al., 2006; Lim et al., 2005; Valencia-
Sanchez et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Biogenesis of microRNA and microRNA-mediated gene regulation in 
animal cells 
 
MicroRNAs are produced from full-length RNA polymerase II transcripts (pri-miRNA) after 
cleavage by two RNAse III enzymes (Drosha and Dicer) in association with accessory 
proteins (RISC). The actions of miRNAs are mediated by the RISC that is believed to 
block mRNA translation, reduce mRNA stability or induce mRNA cleavage, after imperfect 
binding to MREs within the 3’ and 5’ untraslated region (UTR) of target mRNA genes 
(Waldman and Terzic, 2008). 
 
Recent advances in analyzing the spatial expression of miRNAs have shown 
that they are expressed in a very tissue-specific manner during the development 
(Aboobaker et al., 2005; Ason et al., 2006; Kloosterman and Plasterk, 2006; Wienholds 
et al., 2005). In particular miR-1 is expressed in heart, miR-124 in the central nervous 
system and miR-10 in anterior-posterior axis. This suggests microRNAs could be 
involved in the molecular watch controlling the organism development (Figure 1.2). 
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Figure 1.4  Expression of different microRNA 
 
Expression of fifteen miRNAs in 9.5 and 10.5 d.p.c. mouse embryos: miR-10a and miR-
10b, posterior trunk; miR-196a, tailbud; miR-126, blood vessels; miR-125b, midbrain-
hindbrain boundary; miR-219, midbrain, hindbrain and spinal cord; miR-206, somites; 
miR-1, heart and somites; miR-183, miR-182 and miR-96, cranial and dorsal root ganglia; 
miR-17-5p and miR-20 are ubiquitously expressed (Kloosterman et al., 2006). 
 
1.4.2 miRNA gene clusters 
A prominent characteristic of animal microRNA is that their genes are often 
organized in tandem and are closely clustered on the genome (Houbaviy et al., 2003; 
Lau et al., 2001), but they are processed into multiple individual mature miRNA (Stefani 
and Slack, 2008). In many cases, such clustered miRNAs seem to be processed from 
the same polycistronic precursor transcript (a single mRNA molecule produced from 
the transcription of several sequential genes). The genomic organization of these 
miRNA clusters is often highly conserved, suggesting an important role for coordinated 
regulation and function of a set of mRNAs targets (Stefani and Slack, 2008). For 
example, a mammalian miRNA gene-cluster of particular interest encodes the six 
closely related genes miR-290- to miR-295 in mouse. These are expressed specifically 
in embryonic stem (ES) cells. Although it is not yet clear whether the human genome 
contains an orthologous cluster of ES-cell-enriched miRNAs, these findings suggest 
that translational repression of gene expression by miRNAs contributes to the 
maintenance of stem-cell potency (Houbaviy et al., 2003). Clusters can also contain 
miRNAs of distinct sequences and, in this case, each distinct miRNA type may in a 
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coordinate manner deploy towards its target. For example, in mouse, miR-1 localizes in 
a genomic cluster with miR-133 but these two miRNAs differ in their seed sequence, 
and have distinct functions in contrast to miR-1, which promotes myogenesis, miR-133 
inhibits muscle differentiation and induces proliferation by repressing serum response 
factor (Chen et al., 2006). 
The miR-17-92 cluster is a prototypical example of polycistronic miRNA gene. In 
the human genome, the miR-17-92 cluster encodes six miRNAs (miR-17, miR-18a, 
miR-19a, miR-20a, miR-19-b-1, and miR-92-1) which are tightly grouped within an 800 
base-pair region of human chromosome 13 (Figure 1.5A). Both the sequences (Figure 
1.5B) of these mature miRNAs and their organization are highly conserved in all 
vertebrates. The human miR-17-92 cluster is located in the third intron of a ~7 kb 
primary transcript known as C13orf25 (Ota et al., 2004). 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Organization of the miR-17-92 Cluster and its paralogs (Mendell, 2008)  
 
A. The genomic organization and primary transcript structures of the human miR-17-92, 
miR-106a-363, and miR-106b-25 clusters. The miR-106a-363 primary transcript has not 
been characterized. B. Based on their seed sequences- which are the regions considered 
most important for target selection (nucleotides 2-7; shown in blue)- the miRNAs of these 
clusters can be grouped into four families: the miR-17 family (miR-17, miR-20a/b, miR-
10a/b, and miR-93); the miR-18 family (miR-18a/b); the miR-19 family (miR-19a/b); and 
the miR-25 family (miR-25, miR-92a and miR-363). MicroRNAs of the miR-17-92 cluster 
and its paralogs have been implicated in normal development of the heart , lungs, and 
immune system (Koralov et al., 2008; Ventura et al., 2008; Xiao et al., 2008) as well as in 
tumorigenesis.  
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Ancient gene duplications have given rise to two miR-17-92 cluster paralogs in 
mammals: the miR-106b-25 cluster (located on human chromosome 7) and miR-106a-
363 cluster (located on the chromosome X) (Figure 1.5A). The miR-106b-25 cluster is 
located within the 13th intron of the protein-coding gene MCM7. Unlike the miR-17-92 
and miR-106b-25 clusters, which are both abundantly expressed across many tissue 
and cell types, miR-106a-363 cluster was dectable only in same pathological tissues 
such as T-cell leukemia (Landais et al., 2007). Perhaps this polycistronic miRNA 
provides a very specialized function in cell type yet to be studied. 
 
1.4.3 Functions of animal microRNAs 
 Different studies have been taken to elucidate miRNA function and the 
potential phenotypes induced by miRNA perturbations have placed these molecules at 
the centre of critical cellular and developmental pathways. The important role of 
miRNAs in different physiological process in both cells and organisms is supported by 
their conservative sequences and tissue-related expression. Although miRNAs have 
only been studied intensively in the last years, important function for miRNAs in animal 
development and potentially, human disease, have already emerged (Alvarez-Garcia 
and Miska, 2005; Xiao et al., 2008). Indeed, animals without miRNAs cannot live or 
reproduce (Bernstein et al., 2003; Ketting et al., 2001; Wienholds et al., 2003). 
Some miRNAs are regulators of developmental timing controlling proper 
transition among Caenorhabditis elegans larval stages (Wightman et al., 1993) or, as 
let-7, regulate different transcription factors during the larval-to-adult transition acting 
as a master switch that control temporal patterning (Abrahante et al., 2003; Grosshans 
et al., 2005; Lin et al., 2003). 
Although not directly related to signalling cascade, miRNAs often are in 
feedback loops to control their own expression. For example, granulocytic 
differentiation is enhanced by miR-223 expression that is controlled by a feedback 
mechanism (Fazi et al., 2005): before the differentiation process, the transcription 
factor NFI-A allows weak expression of miR-223; upon stimulation with retinoic acid, 
NFI-A is replaced by the transcription factor C/EBPα. That induces high expression of 
miR-223, which, in a reciprocal negative-feedback loop, post-transcriptionally 
represses the expression of NFI-A. 
Many miRNAs show a cellular or region specific expression, in particular in the 
brain, miR-134 is found to localize in synaptic sites of rat hippocampal neurons (Schratt 
et al., 2006), miR-132 is expressed in cortical neurons (Vo et al., 2005), miR-124a is 
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involved in the differentiation of neuronal progenitors into mature neurons by 
degradation of non-neural transcripts (Conaco et al., 2006). The importance of 
microRNA in the functioning brain (Wienholds et al., 2005) is suggested by some 
miRNAs that are implicated in specific asymmetric gene expression in chemosensory 
neurons (Chang et al., 2004; Johnston and Hobert, 2003). For example, lys-6 miRNA is 
expressed in left hemisphere neurons, and miR-273 is expressed in right hemisphere 
neurons. 
Many microRNAs are conserved from worms to mammals. One of the best 
characterized is miR-1, a microRNA involved in formation and maintenance of muscles. 
It is highly expressed in the muscles of larva and Drosophila flies (Aboobaker et al., 
2005; Sokol and Ambros, 2005) and in the muscles and heart of mice (Zhao et al., 
2005). Although miR-1 genetic knockout is not available, over-expression of miR-1 
results in developmental arrest, thin-walled ventricles, and heart failure due to myocyte 
premature differentiation and proliferation defects. 
Other miRNAs appear to be involved in energy homeostasis, in particular 
Drosophila flies with mutated miR-14 display peculiar phenotype: they are obese and 
have elevated levels of triacylglycerol. Thus, miR-14 seems to play a role in fat 
metabolism. In a similar gain-of-function screening for genes affecting tissue growth, 
the miR-278 locus was identified (Teleman et al., 2006): miR-278 mutants are lean and 
have elevated insulin production. 
 
1.4.4 miRNAs and cancer  
The important role of various miRNAs in the determination of various 
physiological patterns can suggest that deregulations of this control system can lead to 
different diseases and tumour formation and progression (Table 1.1). Specific changes 
in miRNA expression were found in tumour tissues with respect to normal tissues (Liu 
et al., 2004; Lu et al., 2005; Volinia et al., 2006). The hypothesis that miRNA loss leads 
to a de-differentiation process and less-differentiated tumours was supported by 
evidence that miRNA induction is closely related to normal cellular differentiation (Lu et 
al., 2005). Since the prognostic power of miRNA profiles is astonishing, their 
importance in developing and maintaining cellular fate is easily drawn. Specific roles of 
miRNAs in certain cancer are established (Table 1.1) (Schickel et al., 2008) and many 
miRNA targets are emerging, explaining and predicting some activities of miRNAs in 
cancer. The microRNA involved in cancer progression are called oncomiRs (Figure 
1.6) (Esquela-Kerscher and Slack, 2006). Oncogenic miRNAs include miR-155 and 
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miR-17-5p. The miRNAs with tumour-suppressing activity include miR-15, miR-16 and 
let-7 (Table 1.1) (Schickel et al., 2008). 
The first evidence for a direct link between miRNAs and human cancer was 
provided by the observations that two microRNA genes, miR-15 and miR-16 located in 
a 30Kb region on chromosome 13, were found deleted or their expression reduced in 
chronic lymphocytic leukemia (CLL) cases (Calin et al., 2002). Another study found that 
miR-143 and miR-145 expression levels were reduced with the more advanced stages 
of colorectal neoplasia (Michael et al., 2003). Both studies were focused on a small 
number of miRNA and based on miRNA cloning and northern blotting approaches. The 
subsequent development of miRNA microarray technologies increased the number of 
miRNA expression studies in human cancer. Crucially, q-PCR for mature miRNA also 
became available for the analysis of small tissue samples and microarray miRNA 
validation (Lu et al., 2005). A current map of all miRNA loci involved in at least two 
different human cancers through their expression profiling lists 56 loci (Figure 1.7) 
(Blenkiron and Miska, 2007). 
In contrast to miR-15/miR-16 expression, whose expression is often reduced in 
cancers, the miR-17-92 cluster (Figure 1.4) is over-expressed in many cancer types 
(Hayashita et al., 2005; He et al., 2005b; Ota et al., 2004). Recently it was found that 
the inhibition of miR-17-5p and miR-20a, two miRNAs of this cluster, address lung 
cancer cells towards apoptosis (Matsubara et al., 2007). miR-20a negatively regulates 
E2F1 (O'Donnell et al., 2005) and E2F3 (Sylvestre et al., 2007), whereas all the three 
E2Fs regulate the expression of miR-17-92 cluster binding its promoter, in an auto 
regulatory feedback loop. The E2F transcriptional networks appear to link cell cycle 
progression to apoptosis. miR-20a over-expression protects cancer cell lines from 
apoptosis, suggesting that oncogenesis promotion by over-expression of miR 17-92 
cluster could be derived by perturbing the E2F network in a way that induces 
proliferation and inhibits apoptosis (Sylvestre et al., 2007). Therefore, perturbation of 
expression levels can induce either proliferation or apoptosis depending on the cellular 
context. 
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Figure 1.6  MicroRNAs can function either as tumour suppressors or oncogenes 
 
a. In normal tissues, microRNA bound to complementary sequences on the target mRNA 
results in the repression of target-gene expression through a block in protein translation or 
altered mRNA stability (not shown). The overall result is normal rates of cell growth, 
proliferation, differentiation and death. b. The expression reduction or deletion of a miRNA 
that functions as a tumour suppressor leads to tumour formation. A reduction in or 
elimination of mature miRNA levels can occur because of defects at any stage of miRNA 
biogenesis (indicated by question marks) and ultimately leads to the inappropriate 
expression of the miRNA-target oncoprotein (purple squares). The overall outcome might 
involve increased proliferation, invasiveness or angiogenesis, decreased levels of 
apoptosis, or undifferentiated or de-differentiated tissue, ultimately leading to tumour 
formation. c. The amplification or over-expression of a miRNA that has an oncogenic role 
would also result in tumour formation. In this situation, increased amounts of the miRNA, 
which might be produced at inappropriate times or in the wrong tissues, would eliminate 
the expression of a miRNA-target tumour-suppressor gene (pink) and lead to cancer 
progression. Increased levels of mature miRNA might occur because of amplification of 
the miRNA gene, a constitutively active promoter, increased efficiency in miRNA 
processing or increased stability of the miRNA (indicated by question marks). ORF, open 
reading frame. (Esquela-Kerscher and Slack, 2006). 
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Figure 1.7  A miRNA cancer map 
 
Chromosome position of miRNAs implicated in human cancer are shown as coloured 
dots. Each dot represents a single miRNA or a miRNA cluster. Colour refer to tumour 
tissue type, as indicated. Only miRNAs, whose expression levels were found to be 
significantly altered in tumours versus normal tissue in at least two tissue types are 
shown. MiRNA identified in at least four different tumour types are also indicated by their 
name. Data were collated from the studies of primary human tumours of the colorectum, 
thyroid, breast, lung, liver, pancreas, uterus and chronic lymphocytic leukemia, 
glioblastoma and neuroblastoma (Blenkiron and Miska, 2007). 
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A key regulator in the activation of the intrinsic apoptosis pathway in response 
to DNA damage, cellular stress and/or improper mitotic stimulation is the p53 protein. 
Several studies (Bommer et al., 2007; Chang et al., 2007; He et al., 2007; Raver-
Shapira et al., 2007; Tarasov et al., 2007) identified miR-34 as a target for p53. He et 
al. (2007) described that miR-34 expression correlates with p53 expression. Using a 
p53-inducible system, they reported that the miR-34 family of miRNAs is directly 
regulated by p53, and that miR-34 mediates growth arrest in multiple cell lines via 
direct 3’-UTR regulation of cell cycle regulatory factors, such as cyclin-E2 (CCNE2), 
cyclin-dependent kinase 4(CDK4) and the hepatocyte growth factor receptor (c-Met). 
Furthermore, miR-34 was shown to directly target E2F3. In addition, miR-34 resulted in 
an increase in caspase-dependent death when introduced into two cell lines (Welch et 
al., 2007) and contributed to an increase in p53-mediated apoptosis (Chang et al., 
2007; Raver-Shapira et al., 2007). miR-34 was therefore described as a general 
sensitizer to apoptosis mainly through its link to p53, although its targets are still 
speculative. On the other hand, TP53INP1 was supposed to be direct target of miR-
155: TP53INP1 is dramatically reduced in its expression in pancreatic ductal 
adenocarcinoma (Gironella et al., 2007) whereas miR-155 is over-expressed in 
pancreatic cancer (Lee et al., 2007). Other miRNAs functionally connected to p53 are 
miR-372 and miR-373, which were identified as oncogenes in testicular germ cell 
tumours, target the tumour suppressor LATS2 and neutralize p53-mediated CDK 
inhibition (Voorhoeve et al., 2006). 
However the number of microRNA implicated in human cancer by expression 
profiling will still increase substantially for two reasons: first, the recent availability of 
commercial microRNA profiling platforms will wide the access to these tools and, 
second, the number of known human microRNA is still increasing. Some general 
themes are emerging from the expression profiles published up today. For example, a 
study of 334 human primary tumours and tissue interrogating the expression of 217 
miRNAs pointed out that many microRNAs are down-regulated in primary tumours 
when compared with normal tissues and that microRNA expression profiles provide 
lineage-specific information and may classify even poorly differentiated tumours (Lu et 
al., 2005). The notion that a set of microRNA may be deregulated in many tumour 
types is also supported by the finding that a large number of microRNAs can be 
implicated, with different functions, in distinct tumour types. For example, miR-21 may 
act as a tumour suppressor regulating PTEN in cholangiocytes (Meng et al., 2006) or 
an oncogene regulating BCL2 in breast cancer line MCF-7 (Si et al., 2007) depending 
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on cellular context. In the same way, let-7, a marker for differentiated tissues, could 
have a set of targets that have tumour-suppressing functions (Brueckner et al., 2007) 
whereas in other contexts (in certain tissues under certain conditions) it may not (Meng 
et al., 2007). It is down regulated in a number of human cancers such as lung, colon, or 
ovarian cancer, and is useful as a prognostic marker for disease outcome (Akao et al., 
2007; Johnson et al., 2005; Shell et al., 2007; Takamizawa et al., 2004; Yanaihara et 
al., 2006). However, it cannot be viewed as a classical tumour suppressor gene 
because it consists of 12 individual genes transcribed from 8 chromosomal loci (Park et 
al., 2007) and, although all 12 miRNAs are predicted to have a similar set of targets, it 
is not clear whether all the twelve have the same function. Another example of miRNA 
with no clearly defined activity with respect to tumorigenesis is miR-24, which, 
depending on the cell type, can either promote or inhibit cell growth (Cheng et al., 
2005). As such, a miRNA can only be considered a tumour suppressor in the particular 
tissue where its expression inhibits the expression of genes considered to have 
oncogenic properties. It is therefore most appropriate to refer to miRNAs that are 
involved in cancer development in more general term as oncomiRs. 
microRNAs have also been found directly linked to metastasis formation. miR-
10b was found to have elevated expression in metastatic breast cancer (Ma et al., 
2007). Exogenous miR-10b increased invasion of established breast cancer cells 
together with increased proliferation both in vitro and in vivo, whereas miR-10b 
inhibition led to a 10-fold reduction of invasion (Ma et al., 2007). Additional miRNAs 
such as miR-335 and miR-126 were identified in vivo as key metastasis suppressors 
(Tavazoie et al., 2008). Recently, the miR-200 family (which includes miR-200a, b, c, 
miR-141 and miR-429) was identified as a powerful master regulator of epithelial to 
mesenchymal transition (EMT), which is viewed as an essential early step in tumour 
metastasis (Gregory et al., 2008; Park et al., 2008). 
 
1.4.5 MicroRNAs as human cancer markers 
In many studies (Landgraf et al., 2007) the microRNAs are described as 
potentially useful for the molecular diagnosis of tumours. 
The expression of many miRNAs is highly specific for tissue and cell type, and 
this specificity is often retained in the corresponding tumour tissues. Identification of 
cell origin by miRNA profiling is more efficient compared with global analysis of 
mRNAs, because miRNAs are not confounded by such a large pool of irrelevant genes 
and are represented by a relatively small number of species. Therefore, miRNAs could 
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facilitate the accurate diagnosis of tumours hard to be classified with respect to the 
tissue origin by conventional means, for example metastatic lesion of unknown primary 
origin (Jeffrey, 2008), a highly aggressive malignancy that poses diagnostic and 
management difficulties (Varadhachary et al., 2004). Deregulation of miRNAs occurs 
frequently during tumorigenesis (Zhang et al., 2007), making them attractive 
candidates for molecular detection of malignancy. A subset of miRNAs can often be 
found up or down-regulated in tumours compared with the normal tissues. The 
differential expression of miRNAs between tumour and normal tissue may be exploited 
in the diagnosis on samples with scant or poorly preserved cells, where the malignancy 
diagnosis through traditional methods could be difficult (Mitchell et al., 2008). 
Moreover, in the non-invasive screening for cancer, alterations in specific miRNAs can 
be similarly detected in uninvolved body fluids such as peripheral blood (Mitchell et al., 
2008). 
miRNAs may also be useful in sub classifying tumour of a particular tissue 
origin (Rosenfeld et al., 2008). Expression of specific miRNAs has been shown to 
correlate with histological subtypes of certain types of cancer, for example, ductal and 
lobular breast carcinoma (Iorio et al., 2005), mucinous and non-mucinous carcinoma of 
the lung (Garfield, 2008; Yanaihara et al., 2006), and papillary, follicular and anaplastic 
thyroid carcinomas (He et al., 2005a; Visone et al., 2007; Weber et al., 2006). Indeed, 
miRNAs play a role in the distinct pathogenetic pathways leading to the different 
histological subtypes, and may be useful as a diagnostic tool in unusual difficult cases. 
There is increasing evidence that miRNAs can be invaluable as a biomarker for 
patient prognosis. For example, a set of differentially expressed miRNAs was identified 
in chronic lymphocytic leukemia that can separate it into prognostic categories (Calin et 
al., 2005). Reduced expression of let-7 and high expression of miR-155 were 
associated with poor survival in human lung cancer (Takamizawa et al., 2004). High 
levels of miR-21 are associated with poor survival and poor therapeutic outcome in 
colon cancer (Schetter et al., 2008). In addition, several miRNAs, including miR-10b, 
miR-126, miR-335, miR-373 and miR-520c were recently found to promote or suppress 
invasion and metastasis in breast cancer cells (Huang et al., 2008; Ma et al., 2007; 
Tavazoie et al., 2008). Some of these miRNAs were also shown to correlate with 
clinical outcome and disease progression in breast cancer. Thus, levels of these 
miRNAs in primary breast tumours could be useful as predictive biomarkers of their 
metastatic potential (Foekens et al., 2008). 
1. INTRODUCTION 
 
 
31 
1.5 Aim of the present work 
The aim of this study was to evaluate the potential of microRNAs as biomarkers 
to add to the already identified genes responsible of sarcoma tumours and add a new 
wedge in the understanding the genes or molecules influencing the process of 
extravasation of sarcoma cells. 
The research was conducted by multidisciplinary approaches described in the 
following objectives: 
• to verify miRNA as possible tumour markers in patients affected by 
osteosarcomas of different grades; 
• to determine the specific intrinsic capability of some sarcoma cell types to in 
vitro transmigrate; 
• to generate microRNA libraries in osteosarcoma cell lines with different 
migration capability; 
• to better describe some microRNAs both for their expression and functional 
role inside cell; 
• to devise an intravital microscopy system useful to study cells’ capability to 
spontaneously invade the lymphatic vessels of the rat pleural cavity. 
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2.1 Cell lines  
Different human cell lines were cultured in humidified atmosphere (5% CO2) 
using D-MEM medium 10%FBS. In particular, MG-63 (ATCC n° CRL-8303), 143B 
(ATCC n° CRL-1427) and Sa-Os-2 (ATCC n° HTB-85) ost eosarcoma cell lines, A-204 
(ATCC n° HTB-8) rhabdomyosarcoma cell line, SW982 ( ATCC n° HTB-93) synovial 
sarcoma cell line, SK-Ut-1 (ATCC n° HTB-114) sarcom a cell line, SK-LMS-1 (ATCC n° 
HTB-88) leiomyosarcoma cell line, HT1080 (ATCC n° C CL-121) fibrosarcoma cell line, 
He-La (ATCC n° CCL-2) cervix adenocarcinoma cell li ne were tested. Mesenchymal 
cells (ATCC n° CRL-1486) and osteoblast cells (ATCC  n° CRL-11372) were used as 
reference lines. 
The murine tumour cell lines, UMR-106 (ATCC n° CRL- 1661) rat osteosarcoma 
cell line, C6 (ATCC n° CCL-107) rat gliosarcoma cel l line, and B-16 (ATCC n° CRL-
6322) mouse melanoma cell line- wild type and containing the over-expression of NG2 
were cultured in humidified atmosphere (5% CO2) using D-MEM medium 10%FBS. 
 
2.2 FATIMA system 
For motility assay, Human Umbilical Vein Endothelial Cells (HUVEC) coming 
from umbilical cords kindly given from Arcispedale Santa Maria Nuova of Reggio Emilia 
(Italy), were used.  
The HUVEC were extracted (Figure 2.1), after 30 minute of incubation with 
0.25% collagenase A (Roche Diagnostic GmbH – Mannheim, Germany). These 
haematic endothelial cells were seeded on a gelatin 1% layer and cultured in 
humidified atmosphere of 5% CO2 using M199 Endothelial medium (Cambrex - 
Rockland, USA) and 20% FBS (Figure 2.1). 
According to Fatima (Spessotto et al., 2002; Spessotto et al., 2000), a day 
before the experiment, 5x104 HUVEC cells were seeded on a transwell insert (Figure 
2.2) provided with a permeable membrane (8µm pore size). These insert (HTS Fluoro 
BLOK tm Insert, Falcon) were previously covered with 1% gelatine. 24 hours later the 
different sarcoma cells tested were collected and stained with 10µg/ml of red dye Fast 
Dil (Molecular Probe – D-3899) in DMEM with 10% FBS for 5 min at 37°C. Then 
15x104 cells were seeded in 100µl of serum free medium. The kinetics of 
transmigration of the different sarcoma cells was determined using Tecan Spectra 
Fluor Instrument, a fluorescent microplate reader, 1.5 ,4.5, 6, 20.5, 26 and 45 hours 
later (Figure 2.2). 
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Figure 2.1  HUVEC extraction 
 
The umbilical vein endothelial cells were conserved at 4°C using two clamps at the end ( A). 
To collect the HUVEC cells, the umbilical cord was washed at least three times with 0.9% 
NaCl solution (B,C,D). and it was filled with collagenase solution (E). The time of collagenase 
reaction was almost 30 minutes (F) and soon afterwards the cells were collected and seeded 
on gelatin substrate (G). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2  FATIMA assay 
 
A. Endothelial haematic cells (HUVEC) were seeded on gelatin substrate on 0.8µm pore 
membrane (blue). B.C. Tumoral cells (orange,) previously colored with Fast Dil, were 
seeded on endothelial monolayer. D. The kinetics of migration was evaluated using a 
microplate reader, six reading in 2 day of experiment. 
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2.3 RNAs extraction and quantification 
Total RNAs were extracted from cells with a confluent density of 75% using 
Trizol® total RNA isolation reagent (Gibco BRL, Life Technologies, Gaitherburg, MD, 
USA), according to the manufacturer’s instruction. The concentration and the purity of 
the samples were measured reading absorbance at 260 and 280 nm using 
BioPhotometr (Eppendorf), while integrity was determined using an electrophoretic run 
on 1% agarose gel. 
 
2.4 Small-RNA library construction 
20-100 µg of MG-63 and 143B osteosarcoma cell lines RNAs were run on an 
8% denaturing polyacrylamide gel (Figure 2.3). The areas between 15 and 30 bp were 
cut and purified with phenol/chloroform standard procedure (Sambrook and Russell, 
2001) and precipitated with 10 µg of glycogen. This small-RNAs fraction was 
dephosphorylated using Calf Intestine Phosphatase (CIP-New England Biolabs, 
Ipswich, MA) followed by ligation of a linker (adaptor) to the 3' end of the RNA using T4 
RNA ligase (New England Biolabs)1. Subsequently a new run on 4% poliacrilamide gel 
and a new purification with phenol/chloroform standard procedure (Sambrook and 
Russell, 2001) were performed and then the two samples were phosphorilated using 
Poly Nucleotide Kinase (PNK) followed by ligation of a linker to the 5' end of the RNA 
using T4 RNA ligase2. First strand cDNA was synthesized using oligo-linker miRclon 
rev primer and AMV-reverse transcriptase (Finnzymes). The resulting cDNA was then 
PCR-amplified for 25 cycles using miRclon fwd3 and miRclon rev4 primer and Phusion 
polymerase (Finnzymes) following program A5 in Gen Amp® PCR System 2700 
(Applied Biosystems) (figure 2.3). After the purification on 8% polyacrylamide gel, the 
fraction of the cDNA in the range of 80–100 bp was reamplified using two times the 
                                                
1 3’ adapter pUUUaaccgcatccttctc 
 
2 5’ adapter tactaatacgactcactAAA 
 
3 miRclon rev 5’ GAC TAG CTG GAA TTC AAG GAT GCG GTT AAA 3’      (Elbashir et. al., 2001) 
 
4 miRclon fwd 5’ CAG CCA ACG GAA TTC ATA CGA CTC ACT AAA 3’      (Elbashir et. al., 2001) 
 
5 program A: 98°C 30” (98°C 10”, 43°C 20”, 72°C 15”) x25, 72°C 7’, ∞16°C 
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same reagents and conditions described above. The products were, then, digested 
with EcoRI enzyme whose sequence was in primers (underlined nucleotides) to 
generate 5' overhangs and the concatemerisation was carried out using T4 DNA ligase 
(New England Biolabs). The purified products, between 300 and 1000 bp, run on low 
melting temperature agarose gel, were ligated in EcoRI sites of TopoTA cloning vector 
(Invitrogen). Ligations were electroporated into DH5α electrocompetent cells 
(Invitrogen) resulting in 106 recombinant clones (Figure 2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3  MicroRNA library preparation  
 
From total RNAs 25 nucleotides small RNA were extracted after electrophoretic run. Consecutively 
two adapter (3’ and 5’) were connected and after EcoRI digestion, the concatemer was bound and 
cloned in TOPO TA vector. The different plasmid products were insert in DH5α cells.  
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2.5 Sequencing of small-RNA cDNA libraries 
Both libraries were plated on Luria-Bertani (LB) ampicilline and kanamicine 
plates and selected colonies, after re-growth were picked up and put in 20µl of water. 
Cells were lysed by heating in PCR machine (Applied Biosystem 7800) which follows 
the program B6 using Go Taq Polimerase (Promega) and the primers seq fwd7 and seq 
rev8 in Gen Amp® PCR System 2700 (Applied Biosystems)9. The PCR products were 
run on 1% agarose gel. The longest amplification products were reamplified, purified 
using Qiaquick Gel extraction Kit (Qiagen GmbH, Hilden-Germany) and 30ng of 
purified DNAs, resuspended in 16µl of H2O, were transferred in a new tube with 4µl of 
DTCS Quick Start Master Mix of Genome Lab Dye Terminator Cycle Sequencing kit 
(Beckmann) and 2µl of M13 forward primer10. Termocycling was performed with 
program C11 on 2700 Applied Biosystems machine. Final products were purified with 
standard procedure using ethanol precipitation and analyzed in Beckman coulter 
CEQTM 2000 DNA Analysis System. 
 
2.6 Sequence analysis 
Base calling and quality timing of sequence chromatogram was done by 
Chromas Lite Sofware. Every sequence was analysed using megablast software 
(http://www.ncbi.nlm.nih.gov/BLAST). After masking of the vector and of the adapter 
sequence and after removing redundancy, inserts of length between 20-23 bases were 
compared with the small RNAs present in miRNA registry 
(http://microrna.sanger.ac.uk/sequences) and mapped to human genome using BLAST 
human genome: http://www.ncbi.nlm.nih.gov/genome/seq/HsBlast.html. Genomic 
                                                
6 program B: 95°C 5’ (95°C 30”, 61°C 30”, 72°C 1’) x3 0, 72°C 7’, ∞16°C 
 
7 Seq fwd 5’ GTT TTC CCA GTC ACG ACG TTG TA 3’ 
 
8 Seq rev 5’ CAC AGG AAA CAG CTA TGA CC 3’ 
 
9 buffer di annealing 10X: 100mM Tris pH 6.9, 400mM KCl, 5mM EDTA) 
 
10 M13 forward primer 5’ TGT AAA ACG ACG GCC AGT 3’ 
 
11 program C:  (96°C 20”, 50°C 20”, 60°C 4’) x30, ∞16°C 
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regions containing inserts with 100nt flanks were retrieved from ENSEMBLE: 
http://www.ensembl.org/Homo_sapiens/ and sliding window of 100 nt was used to 
calculate RNA secondary structures by RNAfold 
(http://www.bioinfo.rpi.edu/applications/mfold/old/DNA/form1.cgi). Only the regions that 
folded into hairpin and contained an insert in one of the hairpin arms were used in 
further analysis. Since every non-redundant insert produced independent hits at this 
stage, hairpins with overlapping genomic coordinates were merged into one region, 
tracing locations of matching inserts which were used in downstream calculations as a 
mature sequence. Next, gene and repeated annotations for hairpin genomic regions 
were retrieved from Ensembl, and repetitive regions as well as ribosomal RNAs, tRNAs 
and snoRNAs were discarded. To find homologous hairpins in other genomes, mature 
regions were blasted against different organisms, in particular human, macaca, 
chimpanzee, ape, mouse, rat, cow, tetraodon, xenopus and fugu genomes. Homologs 
from different organisms were aligned with the original hairpin by clustalw to produce a 
final multiple alignment of the hairpin region. For new sequences that produce hairpins, 
values of thermodynamic were calculated.  
 
2.7 miR-93 and miR-210 expression analysis in tissue and sarcoma cell lines 
Different human adult and fetal tissues12 from Cell Applications Inc. (San Diego, 
CA) and the tumour cell lines described above were used to analised miR-93 and miR-
210 expression. Reverse transcription and RT-Real Time PCR were carried out 
following TaqMan MicroRNA Assay Protocol (Applied Biosystems) and the expression 
of miR-93 and miR-210 was quantified using 2-∆∆CT comparative method (Applied 
Biosystems, User Bulletin N°2 (P/N 4303859). The da ta were presented as log10 of 
relative quantity of target miRNAs, normalized respect U6 as endogenous reference 
(RNU6B 001093-PE Applied Biosystems, Foster City, CA). As relative calibrators we 
used cDNAs, from Mesenchimal Stem Cell for the different tumour cell lines and 
osteoblast cells for osteosarcoma cells. The threshold cycle (Ct) was determined using 
default threshold setting and transcript quantification was performed in duplicate for 
each samples. 
                                                
12
 Bone marrow, Brain Frontal Cortex, Brain Occipital Cortex, Stomach, Spleen, Sketal muscle, Lung, 
Intestine, Pancreas, Heart, Kidney, Prostate, Liver, Fetal eye and Fetal Brain. 
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2.8 Drosha and Dicer analysis in sarcoma cell lines  
The expressions of Drosha and Dicer were analysed using qRT-PCR TaqMan 
in some of the cells described above with specific primers13,14. The expression was 
quantified using 2-∆∆CT comparative method (Applied Biosystems).  
Briefly, RNA was initially reverse transcribed using a High Capacity cDNA 
Archive Kit (Applied Biosystems, CA, USA) and then 10ng were amplified using master 
mix: FluoCycle SYBR (Euroclone) in a 20 µL PCR reaction following the protocol and 
amplification steps: denaturation at 95°C for 5 min , followed by 45 cycles of 
denaturation at 95°C for 15 sec and then annealing at 56°C for 30 sec and extension at 
72°C for 30 sec. The melting curve was performed fr om 55°C to 95°C. All reactions 
were carried out on the Chromo4 Continuous Fluorescence Detector (MJ Research). 
Relative quantitation was carried out, versus GAPDH15 as an endogenous control, 
using the ∆∆Ct method. Transcript quantification was performed in triplicate for each 
sample. 
 
2.9 Cloning and transduction of the osteosarcoma cells 
The gateway system of cloning was used to insert the studied miR-93 and miR-
7 new in pCDBGW-miR vector (Figure 2.4), kindly provided by Prof. Paolo Malatesta 
(Istituto Nazionale per la Ricerca sul Cancro, Genova – Italy). In brief, two 
complementary strands of 60 nt containing miR-93 or miR-7 new were annealed for 4’ 
at 95°C then ligated over night in a pENTRY vector.  After checking the transformation 
in DH5α subcloning cells and the ligation with PvuII (Promega Corporation, Madison, 
WI, USA) and BsrgI (New England Biolabs) enzymes, a clonase reaction with LR 
Clonase (Invitrogen) was performed. The final ligation in pCDBGW-miR was tested 
with MscI restriction enzyme (New England Biolabs).  
                                                
13
 Drosha fwd  5’ GCT CTG TCC GTA TCG ATC AAC T 3’ 
 
 Drosha rev 5’ AAG TGG ACG ATA ATC GGA AAA GT 3’ 
 
 
14
 Dicer fwd 5’ GGC CCC AAT CCT GGA CTT A 3’ 
 
 Dicer rev 5’ AAG CCG CTC CAG GTT AAA TC 3’ 
 
 
15
 GAPDH fwd 5’ CTC TCT GCT CCT CCT GTT CGA C 3’ 
 
 GAPDH rev 5’ TGA GCG ATG TGG CTC GGC T 3’ 
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The vector containing the studied miRNA, was transfected in MG-63, together 
with a vector containing G418 resistence in the ratio of 5:1, using Metafectene reagent 
(Biontex, Munchen - Germany) and following the manufacturer’s protocol. 
For 143B insertion, pCDBGW-miR retrovirus was prepared using CaPO4 and 
HEPES solution following standard procedures. Infection of retrovirus was performed in 
the same cell type after transfection of a plasmid containing ecotropic receptor.  
After two days the green colonies were picked up and put in a single well of a 
96 multiwell. After few days, the colonies of each green well were picked up again and 
splited in a new multiwell 96 (one cell every three wells) (Figure 2.5). The real 
expression of miR-93 was tested as described in paragraph 2.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4  PCDBGW-miR vector  
 
pCDBGW-miR vector is composed of 6183 bp. It is an Ampicillin resistance vector and it was 
modified from pCEG (cutting the IRES-GFP sequence and binding the gateway box) in the 
laboratory of Prof. Malatesta. It contains Cito Megalovirus (CMV) promoter and EmGFP as 
reported gene. The microRNAs were inserted using the gateway system.  
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2.10 Proliferation assay 
The proliferation assay was performed in a 96-well format using CellTitre 96 
One solution Cell proliferation assay (Promega Corporation, Madison, WI, USA). In an 
individual experiment, proliferation under each condition (0%, 0.1%, 1%, 10% FBS) 
was studied in triplicate and the overall experiment was repeated at least twice. 
Figure 2.5  Multiple cloning procedure  
 
pCDBGW-miR vector was infected or transfected in osteosarcoma cells. The green cells where 
selected, amplified and seeded in 96 wells plate to create a single clone.  
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2.11 Search of microRNA targets 
To predict the probable target genes of studied microRNA the results of PicTar 
(http://pictar.mdc-berlin.de/), TargetScan (http://www.targetscan.org/) and Miranda 
(http://microrna.sanger.ac.uk/targets/v5/) bioinformatic softwares were compared. Four 
possible targets of miR-93 (ARID4B16, TXNIP17 ZNFX118, ANK219) were tested20 by 
PCR Real-Time, using SyBr Green (Lonza, Milan-Italy). 
To detect the functional mRNA targets of miR-93 a method described by Vatolin 
(Vatolin et al., 2006) was performed. In brief, a cDNA was synthesized using miRNAs 
as endogenous primer a mRNA template, purified hybrid cDNA-miRNA molecules were 
purified using PCR purification kit (Qiagen) and ligated with a 5’ adapter using T4 RNA 
ligase. A pre-amplification was performed with primers on adapter and miRNA; the new 
synthesized products were then run on 1% agarose gel, purified and sequenced on 
Applied Biosystem machine using Big Dye Terminator kit (Applied Biosystems), 
following the manufacturer’s protocol. 
 
2.12 Global microRNA expression analysis 
miRNA expression levels were examined using the Applied Biosystems 
TaqMan® Low Density Array (cod. 4384792) consisting of 365  well characterized 
miRNAs and 2 nucleolar RNAs (snoRNAs) as endogenous controls for data 
normalization. Single stranded cDNA was generated from total RNA sample by reverse 
                                                
16
 ARID4 B fwd: 5’ GAG GAG AGG AAT ATA ATA CCA A 3’ 
 ARID4 B rev: 5’ CCT GAT CAG AAT GTG TAG GT 3’ 
 
17 TXNIP fwd: 5’ GTG TGA AGT TAC TCG TGT CA 3’ 
 TXNIP rev: 5’ CTT CCA GAA GAA GCG TGT CT 3’ 
 
18 ZNFX1 fwd: 5’ CTC CTA ACC AAC GAG TCT GT 3’ 
 ZNFX1 rev: 5’ GCT GGT CTT CTG ACA ATT GT 3’ 
 
19 ANK2 fwd:  5’ TGC ATC TTT GGC TGG ACA AG 3’ 
 ANK2 rev: 5’ CAG TGC TCT GAT TAG CTC CA 3’ 
 
20 program D:  95°C 5’ (95°C 30”, 56-60°C gradient  30 ”, 72°C 30”) x30, 72°C 7’, ∞16°C 
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transcription using the Applied Biosystems TaqMan MicroRNA Multi Reverse 
Transcription Human pool set (cod. 4384791), following manufacturer's protocol. 
Briefly, RT reactions contained 80 ng of total RNA, 1X RT buffer, 0.20 mM each of 
dNTPs, 0,01 U Reverse Transcriptase and 0.25 U RNase Inhibitor and 1 µl of specific 
primer pool. PCR amplification was carried out on the Applied Biosystems 7900 Real-
Time PCR system. Arrays were incubated at 50°C for 2 min then 94.5°C for 10 min, 
followed by 40 cycles of 97°C for 30 s and 59.7°C f or 1 min. The array was run in 
duplicate for each case to allow the assessment of technical variability, the relative 
quantitation was carried out using the ∆∆CT method. Expression of miRNA was 
normalized versus an endogenous control RNU48 and normal osteoblast cells were 
used as calibrators. 
 
2.13 DNA microarray analysis 
The infected/transfected miR-93 and miR-7 new MG-63 and 143B 
osteosarcoma cell lines RNAs (extracted using Rnase kit -Qiagen GmbH, Hilden – 
Germany- according to manufacturing protocols) were analysed on 1% agarose gel 
and quantified using Nanodrop ND1000 (NanoDrop Technologies, Wilmington, DE, 
USA) and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) was 
employed to confirm the quality of the samples. 
For the study of gene expression, an Agilent high density slide containing 4 X 
41,000 60-mer oligonucleotide probes was used and the two colours technology was 
applied 
500 µg of each infected/transfected RNA sample were reverse transcripted to 
cDNA, amplified and then transcripted in cRNA and labelled with Cy5 dye following 
Agilent’s Two-Color Microarray-Based Gene Expression Analysis protocol. Each 
sample was mixed with the same amount of Cy3-labeled product from a MG-63 or 
143B used as RNA reference. Spike-in RNA (Agilent Technologies, Palo Alto, CA, 
USA) was used as internal control. The post labelling efficiency was quantified both by 
Nanodrop to check the amplification and the dye incorporation, and by Bioanalyzer to 
check the cRNA integrity. The two different labelled cDNA were then hybridized 
together on slides for 16 hour at 37°C. 
After washing, slides were scanned with an Agilent's G2565AA Microarray 
Scanner System. Dye-normalized, background-subtracted log-ratios of sample to 
reference expression were calculated using Agilent’s Feature Extraction Software v9.5. 
Hybridization quality was checked using the software’s quality report. 
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2.14 Intravital microscopy 
UMR-106 and B16 cells (2X106) were colored with green viable dye (Cell 
Tracker Green - Molecular Probes) and introduced in pleural cavity of a female rat 
(Figure 2.6). After 12, 24, 30 and 48 hours the rats were sacrificed, diaphragms were 
documented using a 3D camera (Figure 2.7) and cryo-prepared for histological 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
Figura 2.6  Intravital microscopy procedure 
 
2X106 tumour cells previously coloured with a vital staining were introduced in the pleural 
cavity of a female rat. The spreading of the tumoral cells were evaluated in the mesenteric 
duct of diaphragm. This evaluation was performed using stereomicroscopy and 3D 
camera. 
 
 
 
 
 
 
 
 
 
 
 
Figura 2.7  Analysis using 3D camera 
 
The diaphragm was analysed and documented using 3D camera. The tumour cells 
appeared as a white spot. 
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3.1 microRNA expression in surgical samples of osteosarcoma samples 
Preliminary analyses were carried out on three osteosarcoma cell lines to 
identify microRNAs expressed by these tumour cells. Their over-expression and down-
regulation (Table 3.1 and Table 3.2) were detected by using the pre-cast microRNA 
platform cards. 
Table 3.1  microRNA up-expressed by three osteosarcoma cell lines 
 
143B MG-63 U2Os 
microRNA Expression microRNA Expression microRNA Expression 
  
  
 
  
  
miR-9 10.130  miR-9 150.640  miR-7 4.150  
miR-183 10.180  miR-24 3.190  miR-9 49.860  
miR-196a 2.600  miR-31 6.570  miR-28 4.590  
miR-330 14.120  miR-151 2.530  miR-30d 2.670  
miR-326 3.270  miR-152 3.170  miR-99b 3.810  
miR-342 2.950  miR-155 2.770  miR-126 5.980  
miR-449 4.140  miR-183 17.210  miR-148 3,780  
miR-484 3.250  miR-196a 6.170  miR-151 3.450  
miR-550 2.440  miR-484 4.890  miR-183 39.950  
 
 
 
 
 
 miR-194 5.330  
 
 
 
 
 
 miR-196a 3.200  
 
 
 
 
 
 miR-200c 12.340  
 
 
 
 
 
 miR-203 24.000  
 
 
 
 
 
 miR-330 3.160  
 
 
 
 
 
 miR-362 4.720  
 
 
 
 
 
 miR-484 1.960  
 
 
 
 
 
 miR-550 2.600  
 
Table 3.2  microRNA down-expressed by three osteosarcoma cell lines 
 
Tumour Cell Line microRNA Expression 
      
143B miR-125b 0.035 
 miR-214 0.047 
    
 
MG-63 miR-27b 0.052 
 
miR-135b 0.041 
 
miR-200c 0.014 
 
miR-133b 0.094 
 
 
 
U2Os miR-146a 0.082 
 
miR-155 0.015 
 
miR-134 0.011 
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To further examine the microRNAs expressed in patients affected by 
osteosarcomas of different grades, the four microRNAs found to be over-expressed in 
the three cell lines (Table 3.3) were analysed in surgical specimens of patients with low 
and high grade osteosarcomas. 
 
Table 3.3  microRNA up-regulated in all osteosarcoma cell lines 
 
Tumour Cell line miR-9 miR-183 miR-196a miR-484 
     
143B 10.126 34.178 2.602 3.249 
     
MG-63 150.644 17.208 6.169 4.890 
     
U2OS 49.864 39.948 3.204 1.693 
 
We chose to analyse those also considering that three of four microRNAs 
detected in cell lines have already been described as important in various cellular 
pathways. 
For istance, miR-9 is expressed at high levels during human pancreatic islet 
development (Joglekar et al., 2009). It is important as transcriptoma guardian showing 
a down-regulation during oligodendrocyte differentiation (Lau et al., 2008). Moreover, it 
promotes cell growth arrest and apoptosis in medulloblastoma (Ferretti et al., 2009). 
miR-9 up-regulation in osteoarthritic cartilage and bone tissue (Jones et al., 2008) 
suggests this microRNA as a mediator in inflammatory function and pathways. 
miR-183 has been identified as a potential metastasis-inhibitor in lung cancer 
regulating the expression of other genes involved in migration and invasion (Wang et 
al., 2008a). Another study (Loscher et al., 2008) suggests a relationship between miR-
183 down-regulation and retinal degeneration. 
miR-196a is reported to decrease human adipose tissue-derived mesenchymal 
stem cell proliferation and enhance osteogenic differentiation (Kim et al., 2008). In 
chronic pancreatitis and pancreatic cancer, miR-196a permits to discriminate normal 
from altered pancreas tissues (Szafranska et al., 2007) and its over-expression is 
considered to play a role in poor survival prediction (Bloomston et al., 2007). 
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Low grade osteosarcoma - The four microRNAs resulted differently expressed 
in the surgical samples of low grade osteosarcoma patients (Figure 3.1), but none of 
these samples seemed to be characteristic of this tumour type. miR-9 and miR-183 
expression in patients was low, if we compare to the three cell lines previously 
investigated. Only one of the samples showed a relatively high expression of miR-
196a, with levels equivalent in the cell lines (Table 3.2). A certain uniformity of miR-484 
expression was found in all the subjects but the lack of a healthy control tissue did not 
permit to establish if microRNA could be a tumour marker in this osteosarcoma grade 
(up-or down- regulation?). Further studies on a wider patient cohort have to be 
performed for a better definition of the significance of the expression pattern of these 
microRNAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1  Analysis of pre-selected microRNA on surgical samples of low 
osteosarcoma grade 
 
Expression analysis of miR-9, miR-183, miR-196a and miR-484. 
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High grade osteosarcoma – A comparison of microRNA expression in tumoral 
and normal tissues was carried out in surgical samples from patients with high grade 
osteosarcoma (Figure 3.2). The normal tissue came from the surgical lesion edge of 
the same patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Pre-selected microRNA on surgical samples of high osteosarcoma grade 
 
The analysis was carried out on normal (N) and tumour (T) tissue samples of the same 
patient. 
 
Data analysis pointed out a great heterogeneity of microRNA expression among 
patient normal tissues (Figure 3.2; Table 3.4). In particular: (i) miR-9 resulted like 
osteoblast control expression21 in one sample, down-regulated in another, and over-
expressed, in a similar manner, in two patients; (ii) miR-196a was weakly down-
                                                
21
 Osteoblast cells were used as control since classical osteosarcoma originates from the bone made up of 
mesenchymal cells, which tend to produce bone substance that is to be differentiated in a osteoblastic 
sense (Campanacci, 1990). 
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regulated in one sample and up-regulated in the others, even if with completely 
different levels; (iii) both miR-484 and miR-183 were up-regulated in comparison to 
primary osteoblasts. When considering the patient with the lowest expression (≈ 3) of 
miR-484 in its normal tissue, all samples of both low (Figure 3.1) and high (Figure 3.2) 
grade osteosarcoma had down-regulated miR-484. Also miR-183 resulted down-
regulated in neoplastic lesion with respect to the normal tissue of the lesion edge 
(Figures 3.1 and 3.2). 
Although in all samples of high osteosarcoma grade we observed a microRNA 
down modulation, only miR-484 and miR-183 could be considered as possible 
biomarkers for these tumours. These results, obtained in collaboration with the group of 
Dr. Maria Serena Benassi (Istituti Ortopedici Rizzoli, Bologna, Italy), need to be widen 
to encompass a larger number of cases to better understand the neoplastic role of 
these microRNAs and the correlation between their different expression pattern and 
prognosis of these diseases.  
 
Table 3.4  microRNA expression in tumour samples of high grade 
osteosarcoma patients (1-4) 
 
 
1  2  3  4  
 
miR-484 168.664  2.596  9535.000  34.488 
 
 
miR-196a 35.770  0.492  979.109  369.967 
 
 
miR-183 82.711  455.087  37771.000  151.167 
 
 
miR-9 19.835  0.311  1.010  19.835 
 
 
3.2 Transmigration of tumour cells 
To increase the knowledge of molecules important in metastasis formation and 
in particular the process of extravasation, spreading, we set up an assay using HUVEC 
and a Transwell system as described in Materials and Methods. The kinetics of 
transmigration of different sarcoma and other tumour cell lines obtained by using a 
fluorescent microplate reader is reported in Figure 3.3. 
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Figure 3.3  Kinetics of transendothelial migration of a panel of tumour cells 
 
Graphic representation of the migration kinetics of different tumour cell types. Rhomboid 
marks: osteosarcoma cell lines; circle marks: sarcoma cell lines; triangle marks: 
haematological tumour cell lines; star marks: different types of carcinoma.  
 
In this type of assay, the three osteosarcoma cell lines showed a migration 
capability different from that of other sarcoma and non-sarcoma cell lines. From a 
regression analysis (Figure 3.4), a very similar migration behaviour was observed for 
MG-63 and Saos-2 osteosarcoma cell lines. Both showed an identical transmigration 
movement for time unit (≈0.75), whereas, the 143B cell line migrated with about half 
the speed in comparison with the others two osteosarcoma lines. 
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Having observed this different behaviour in the studied osteosarcoma cell lines, 
we performed further investigations on MG-63 and 143B cell lines. Furthermore, we 
consider the expression analysis of some oncosuppressor genes. MG-63 and Saos-2 
are both p21 positive (Li et al., 1999; Merli et al., 1999) and p53 negative (Fogal et al., 
2000; Lauricella et al., 2001). Saos-2 expresses p14 and p16 (Munro et al., 1999) but 
lacks of Rb functional product (Lauricella et al., 2003; Li et al., 1999) whereas MG-63 
shows the Rb expression (Merli et al., 1999) but lacks of both p14 and p16 (Park et al., 
2002). Expression analysis on 143B sarcoma cell lines shows the presence of p53 
(Rajkumar and Yamuna, 2008) and Rb (Benassi personal communication). For our 
further investigations we referred to p53 different expression in the osteosarcoma cell 
lines considered (143B and MG-63) maintaining the presence of Rb expression to 
reduce their difference. 
 
Figure 3.4  Regression analysis of the transendothelial migration kinetics of 
osteosarcoma cell lines 
 
Saos-2 and MG-63 show a similar migration behaviour whereas 143B shows an half 
regression coefficient. 
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3.3 Screening of microRNA libraries 
microRNA library was prepared using RNA with good quality (Figure 3.5A) on 
the two chosen cell lines (143B and MG-63) in agreement with standard procedures as 
described in Mat & Met. The bacterial colonies used for PCR amplification were grown 
on LB agar plate (Figure 3.5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PCR sample run was performed on 1% agarose gel (Figure 3.6) and 
selected products were then sequenced. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5  Libraries preparation 
 
A .Electrophoretic run of MG-63 and 143B RNAs. B. Bacterial clone growth on master LB 
plate. 
Figure 3.6  Screening preparation 
 
Electrophoretic run of PCR products. In red square are highlighted the fragments chose 
for the following sequencing. 
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The sequencing analysis of concatamer with 500-600 bp identified the following 
microRNAs (Table 3.5). 
 
 
 
miRNA sequence size localization MG-63 143B 
miR-16-1  UAGCAGCACGUAAAUAUUGGCG  22 nt 13q14.2 x x 
miR-16-2  UAGCAGCACGUAAAUAUUGGCG  22 nt 3q25.33 x x 
miR-17-5p*  CAAAGUGCUUACAGUGCAGGUAG  23 nt 13q31.3 x x 
miR-20a*  UAAAGUGCUUAUAGUGCAGGUAG  23 nt 13q31.3 x  
miR-20b*  CAAAGUGCUCAUAGUGCAGGUAG  22 nt Xq26.3 x  
miR-21  UAGCUUAUCAGACUGAUGUUGA  22 nt 17q23.2 x  
miR-24-1  UGGCUCAGUUCAGCAGGAACAG  22 nt 19 p13.12  x 
miR-24-2  UGGCUCAGUUCAGCAGGAACAG 22 nt 19 p13.12  x 
miR-93*  CAAAGUGCUGUUCGUGCAGGUAG  23 nt 7q22.1 x x 
miR-103  AGCAGCAUUGUACAGGGCUAUGA  23 nt 20p13 x  
miR-106a*  AAAAGUGCUUACAGUGCAGGUAG  23 nt Xq26.2 x  
miR-106b*  UAAAGUGCUGACAGUGCAGAU  21 nt 7q22.1 x  
miR-107  AGCAGCAUUGUACAGGGCUAUCA  23 nt 10q23.31 x  
miR-130a  CAGUGCAAUGUUAAAAGGGCAU  22 nt 11q12.1 x x 
miR-130b  CAGUGCAAUGAUGAAAGGGCAU  22 nt 22q11.21 x x 
miR-139  UCUACAGUGCACGUGUCUCCAG  22 nt 11q13.4 x  
miR-195  UAGCAGCACAGAAAUAUUGGC  21 nt 17p13.1 x  
miR-210  CUGUGCGUGUGACAGCGGCUGA  22 nt 11p15.5 x  
miR-323  CACAUUACACGGUCGACCUCU  21 nt 14q32.31  x 
 
* microRNAs of miR-17 family that belongs to miR-17-92 cluster 
 
3.3.1 Hsa22 miR16-1 and Hsa miR-16-2 
These two microRNAs (Figure 3.7) have the same sequence but localize in two 
different chromosomes, probably as a result of gene duplication. Only miR-16-1 is well 
known because it resides within the same cluster of miR-15, cluster that seems to 
control the anti-apoptotic gene BCL2 (Cimmino et al., 2005). Deletion or down-
regulation of this cluster is associated with poor prognosis in chronic lymphocytic 
leukemia (Calin et al., 2008; Calin et al., 2005). miR-16-1 and miR-16-2 were found 
down regulated in pituitary adenomas (Bottoni et al., 2005). Recent studies report that 
miR-16-1 acts as tumour suppressor gene by targeting both CCND1 (encoding cyclin 
D1) (Chen et al., 2008b) and WNT3A (in prostate cancer), and by controlling cell 
survival, proliferation and invasion (Bonci et al., 2008). 
 
                                                
22
 Hsa: Homo sapiens 
Table 3.5  microRNAs expressed in MG-63 and 143B osteosarcoma cell lines 
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3.3.2 Hsa miR-17-5p 
miR-17-5p (Figure 3.8) was characterized as microRNA associated to different 
cancer types (Volinia et al., 2006), able to regulate cancer cell proliferation (Hossain et 
al., 2006). In particular its expression level was significantly up-regulated in bladder 
cancer compared to normal bladder mucosa (Gottardo et al., 2007). It was already 
found stably expressed in osteosarcoma cell line SOPS-9607 and osteosarcoma 
tissues (Gao et al., 2007). Moreover miR-17-5p was over-expressed in ectopic and 
eutopic endometrium compared to normal endometrium having, indeed, direct 
implications in the pathogenesis of endometriosis (Toloubeydokhti et al., 2008). 
Figure 3.7  miR-16-1 and miR-16-2 
 
miR-16-1 and miR-16-2 are localized respectively in 13q14.2 and 3q25.33 of the human 
genome. They are a part of miR-15 family. A. Secondary structure prediction of pre-
miRNA, ∆G = -36.70. B. Electropherogram of a sequenced fragment, in yellow, miR-16. 
C. Phylogenetic conservation of miR-16s, in grey the seed region. 
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Although this microRNA is normally expressed within the mesoderm of gastrulating 
embryos during mammalian development (Foshay and Gallicano, 2008), a tight 
correlation was found between miR-17-5p and amyloid precursor protein during brain 
development and neuron differentiation (Hebert et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.3 Hsa miR-20a 
Over-expression of this microRNA (Figure 3.9) was found in different tumour 
types (Volinia et al., 2006) and seems to modulate cell cycle progression (Pickering et 
al., 2009). Recently Poliseno and colleagues (Poliseno et al., 2008) revaluated miR-
20a as a tumour suppressor and found out its role in inducing senescence.  
Figure 3.8  miR-17-5p 
 
miR-17-5p is a part of the miR-17 family and it localized in cluster on the human  
chromosome 13 (see Introduction). A. Secondary structure prediction of stable miR-17-
5p, ∆G = -34.30. B. Phylogenetic conservation of miR-17-5p, in grey the seed region. 
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3.3.4 Hsa miR-20b 
miR-20b (Figure 3.10) is over-expressed in human T-cell leukemias (Landais et 
al., 2007) as well as in c-Myc positive mammary tumours (Sun et al., 2008). In a recent 
study investigating the translation regulation in osteoblasts exposed to porous 
polyethylene (Medpor), miR-20b was found to be one of the microRNAs significantly 
up-regulated in Medpor-treated MG-63 osteosarcoma cells (Palmieri et al., 2008). 
 
 
 
 
 
Figure 3.9  miR-20a 
 
miR-20a is closely clustered to miR-17-5p on the chromosome 13. A. Secondary structure 
prediction of pre-miRNA, ∆G = -31.00. B. Phylogenetic conservation of this microRNA, in 
grey the seed region. 
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3.3.5 Hsa miR-21 
miR-21 (Figure 3.11) appears to function as an anti-apoptosis factor in 
glioblastomas by regulating the tumour suppressor gene PDCD4  (Chen et al., 2008c). 
Indeed, it is considered an onco-microRNA that acts by promoting tumour cell growth, 
invasion and metastasis. In particular, in breast cancer, high miR-21 expression is 
associated with features of aggressive disease, including high tumour grade, negative 
hormone receptor status and ductal carcinoma. Moreover, even through miR-21 was 
correlated with a specific breast cancer biopathologic features (Yan et al., 2008), its 
high expression was associated with poor disease-free survival in early stage patients 
(Qian et al., 2008). These data suggest miR-21 as possible marker in breast cancer. 
Figure 3.10  miR-20b 
 
Mature microRNA has the same sequence of miR-20a but it localized on Xq26.3 of the 
human genome. It belong to miR-17 family. A. Secondary structure prediction of pre-
miRNA, ∆G = -29.80. B. Phylogenetic conservation of miR-20b, in grey the seed region. 
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Other studies showed that its high expression significantly enhances cell proliferation 
and invasion in a gastric cancer cell line suggesting the importance of this microRNA in 
this tumour type too (Zhang et al., 2008). On the other hand, in non-small cell lung 
cancer, miR-21 over-expression directly correlates with overall survival of the patients 
(Markou et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11  miR-21 
 
miR-21 is a part of the miR-21 family and it is localized on the 17q23.2 human 
chromosome. A. Secondary structure prediction of stable miR-21, ∆G = -35.80. B. 
Phylogenetic conservation of this microRNA, in grey the seed region.  
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3.3.6 Hsa miR-24-1 Hsa miR-24-2 
They are two microRNAs (Figure 3.12) located in tandem on chromosome 19. 
Probably they are the result of gene duplication and no one polimorfism could 
distinguish them. They are part of miR-24 family and they were identified in human fetal 
liver (Fu et al., 2005) and in different cell lines and tissue types (Landgraf et al., 2007) 
and, after the modulation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), in 
HL-60 cells (Kasashima et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12  miR-24-1 and miR-24-2 
 
miR-24-1 and miR-24-2 belong to the miR-24 family. A. Stable secondary structure 
prediction of pre-miRNA, ∆G = -26.30. B. Phylogenetic conservation of miR-24-1 and 
miR-24-2, in grey the seed region. 
3. RESULTS AND DISCUSSION 
 
 
61 
3.3.7 Hsa miR-93 
miR-93 (Figure 3.13) is transcribed in the same RNA together miR-106b and 
miR-25 giving origin to a miR-cluster (see Introduction). It is highly expressed in 
primary peripheral blood mononuclear cell from adult T-cell leukemia patients where it 
seems to regulate TP53INP1 (Yeung et al., 2008). In gastric cancer it seems to be 
involved in E2F1 post-transcriptional regulation and may play a key role in the 
modulation of TGF-beta signaling in this tumour type (Petrocca et al., 2008). It is a 
potential biomarker in ovarian cancer since it was found over-expressed in the serum 
of cancer patients when compared to the controls (Resnick et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13  miR-93 
 
mR-93, together with other cluster microRNAs of the miR-17 family localized on 7q22.1 
chromosome of the human genome. A. Secondary microRNA structure prediction, ∆G = -
44.80. B. Electropherogram of a sequenced fragment, in yellow miR-93. C. Phylogenetic 
conservation of this microRNA, in grey the seed region. 
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3.3.8 Hsa miR-103 
mir-103 (Figure 3.14) is significantly up-regulated in bladder cancer compared 
to normal bladder (Gottardo et al., 2007). Its high expression correlates with poor 
survival in esophageal cancer (Guo et al., 2008). In a multifactorial disease as 
osteoarthritis, its relationship with BMI (body mass index) could be useful for the 
development of new therapies (Iliopoulos et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.9 Hsa miR-106a 
miR-106a (Figure 3.15) was widely studied in different tumour types. In 
particular in gastric carcinoma (Xiao et al., 2009) its expression was significantly higher 
than in non-tumour tissue and it was associated with tumour stage, size and 
differentiation. In colon cancer patients (Diaz et al., 2008) the deregulation of miR-106a 
was considered as a marker of disease–free survival and overall survival independently 
Figure 3.14  miR-103 
 
miR-103 is a part of the miR-103 family, it localizes on the human chromosome 20p13. A. 
Stable microRNA secondary structure prediction, ∆G = -28.10. B. Graphic sequence of 
sequenced fragment, in yellow miR-103. C. Phylogenetic conservation of miR-103, in grey 
the seed region. 
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from tumour stage. Moreover, the inverse correlation with E2F1 supports the 
hypothesis that miR-106a targets this transcription factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15  miR-106a 
 
miR-106 is a part of the miR-17 family and it localizes in the Xq26.2 human chromosome 
position. A. Stable secondary structure of pre-miRNA predicted, ∆G = -34.70. B. 
Electropherogram of a sequence, in yellow miR-106a. C. Phylogenetic analysis 
conservation of this microRNA, in grey the seed region. 
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3.3.10 Hsa miR-106b 
Together with its family (miR-17 family), mir-106b (Figure 3.16) was found 
involved in the cell cycle progression by modulating checkpoint function (Ivanovska et 
al., 2008). It was over-expressed in multiple myeloma pathogenesis (Pichiorri et al., 
2008) and in prostate cancer (Ambs et al., 2008). Alterations of its nucleotide sequence 
were found in hepatocellular carcinomas (Yang et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16  miR-106b 
 
miR-106b has very similar mature sequence to miR-106a, but it localizes on chromosome 
7q22.1 of the human genome. It belongs to the miR-17 family. A. Secondary structure 
prediction of pre-miR-106b, ∆G = -43.90. B. Phylogenetic conservation of this microRNA, 
in grey the seed region. 
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3.3.11 Hsa miR-107 
miR-107 (Figure 3.17) is localized on chromosome 10 and seems associated 
with traumatic brain injury (Redell et al., 2008). In the brain of Alzheimer’s disease 
patients miR-107 levels are significantly decreased even in the earliest stages of the 
pathology, resulting involved in accelerated disease progression through regulation of 
beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) (Wang et al., 2008b). 
In tumoural field, miR-107 down-regulation was found in pancreatic and acinar tumours 
(Roldo et al., 2006) and in hepatocellular tumours specifically associated with 
Hepatocyte Nuclear Factor 1α (Ladeiro et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17  miR-107 
 
miR-107 is one of the member of the miR-103 family and has a very similar sequence to 
miR-103. It is located on chromosome 10q23.31 of the human genome. A. Stable 
secondary structure predictied, ∆G = -29.60. B. Sequence fragment electropherogram, in 
yellow microRNA 107. C. Phylogenetic analysis of this microRNA, in grey the seed region. 
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3.3.12 Hsa miR-130a 
MicroRNA 130a (Figure 3.18) was identified in recent studies aimed to the 
identification of factors that regulates the expression of homeoboxes GAX and HOXA5, 
molecules that inhibit the angiogenesis in vascular endothelial cells (Chen and Gorski, 
2008; Urbich et al., 2008). It was down-regulated in ovarian cancer cell lines resistant 
to the chemotherapy. This down-regulation was linked to the translation activation of M-
CSF gene, a well-known resistance factor for ovarian cancer (Sorrentino et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18  miR-130a 
 
miR-130 belongs to the miR-130 family and it is located on human chromosome 11q12.1. 
A. Secondary structure predicted, ∆G = -42.60. B. Graphical sequence of a cloned 
fragment, in yellow miR-130a. C. Analysis of genetic conservation of this microRNA, in 
grey the seed region. 
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3.3.13 Hsa miR-130b 
miR-130b (Figure 3.19) was studied in the brain of schizophrenia patients 
(Burmistrova et al., 2007) but no statically association was found. Recently it was 
studied in HTLV-1 cells and it seemed implicated in the increasing of their apoptosis 
(Yeung et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19  miR-130b 
 
miR-130b is located on chromosome 22q11.21 of the human genome. It belongs to the 
miR-130 family and it distinguished from 130a for one nucleotide. A. Stable secondary 
structure predicted, ∆G = -35.30. B. Phylogenetic conservation analysis of this microRNA, 
in grey the seed region. 
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3.3.14 Hsa miR-139 
miR-139 (Figure 3.20) was found up-regulated in human bronchial squamous 
carcinoma (Mascaux et al., 2008) resulting an useful tool for early detection of lung 
cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20  miR-139 
 
miR-139 is on the same human chromosome of miR-130a but localizes in 11q13.4 
position. miR-139 is a part of the miR-139 family. A. Predicted secondary structure, ∆G = 
-33.40. B. Phylogenetic conservation of this microRNA, in grey the seed region. 
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3.3.15 Hsa miR-195 
In a recent research (Flavin et al., 2008), miR-195 (Figure 3.21) may play a 
potential role as a tumour suppressor gene in primary peritoneal carcinoma in patients 
with ovarian serous carcinoma. It seems to be an important element in starting to 
determine the stress-response that can evoke cardiac hypertrophy and heart failure in 
transgenic mice (van Rooij et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21  miR-195 
 
Together with miR-15 and miR-16 belongs to the miR-15 family. It is located on 17p13.1 
human chromosome. A. Secondary structure predicted, ∆G = -47.50. B. Analysis of 
phylogenetic conservation of this microRNA, in grey the seed region. 
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3.3.16 Hsa miR-210 
In ovarian cancer (Giannakakis et al., 2008) miR-210 (Figure 3.22) was the 
most prominent microRNA consistently stimulated under hypoxic conditions and it 
seemed to play a crucial role in tumour onset by regulating the E2F3 transcription 
factor, a key protein in cell cycle (Giannakakis et al., 2008). Moreover miR-210 over-
expression in normo-oxigenated endothelial cells stimulated the formation of capillary-
like structures on Matrigel and the vascular migration of endothelial growth factor-
driven cell. In this framework it seems to control the expression of Ephrin-A3, an 
inhibitor molecule of tubulogenesis and chemotaxis (Fasanaro et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22  miR-210 
 
miR-210 is located on 11p15.5 human chromosome, it belongs to the miR-210 family. A. 
Predicted secondary structure of pre-miRNA, ∆G = 59.60. B. Electropherogram of a 
sequenced fragment, in yellow, miR-210. C. Phylogenetic analysis of miR-210, in grey the 
seed region. 
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3.3.17 Hsa miR-323 
In acute myeloid leukaemia up-regulation of miR-323 (Figure 3.23) could be a 
marker that could sub-classify the disease and determine its etiology (Dixon-McIver et 
al., 2008). It is highly expressed in human leiomyoma compared to normal myometrium 
and could play a role in the uterine pathogenesis (Marsh et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23  miR-323 
 
miR-323 is localized on the human chromosome 14, in the position 14q32.31, it belongs 
to the miR-154 family. A. Predicted secondary structure visualization, ∆G = -34.50. B. 
Analysis of phylogenetic conservation of this microRNA, in grey the seed region. 
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3.4 Identification of a new microRNA 
An unknown sequence, not yet reported in microRNA database, was found 
expressed in MG-63 cell line. This putative microRNA, localized in 7p15.2 human 
chromosome, was called miR-7 new (Figure 3.24A). From a structural analysis of pre-
miRNA, i.e. harping stability, the sequence of miR-7 new showed a ∆G = -45.50 that 
represents an acceptable stability value (Figure 3.24B). Moreover, a phylogenetic 
analysis through data bases revealed the sequence conservation (Figure 3.24C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24  MicroRNA 7 new 
 
A. Electropherogram of a miR-7 new (yellow rectangle). B. Predicted secondary structure. 
C. Analysis of phylogenetic conservation of this new putative microRNA. 
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3.5 Drosha and Dicer analysis 
MicroRNA maturation is reported up to date as being mediated by two 
enzymes, Drosha in the nucleus and Dicer in the cytoplasm (Hammond, 2005; Lee et 
al., 2003). A study on the expression of both enzymes was carried out in collaboration 
with Dr. Claudio Casoli (Dipartimento di Scienze Biomediche – Ospedale “Luigi Sacco” 
(Milano), Università degli Studi di Milano, Italy). It was found that Drosha was over-
expressed in two of the osteosarcoma cell lines (MG-63 and Saos-2) whereas Dicer 
was found similarly up- regulated in the same two cell lines and down-regulated in 
143B osteosarcoma cell line (Figure 3.25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is interesting to recall the different transendothelial migration kinetics (Figure 
3.4) of 143B cells with respect to the other two osteosarcoma lines. There seems to be 
an apparent relationship between Drosha and Dicer expression and cell migration 
capability of the cells that needs further investigation. 
 
 
Figure 3.25  Drosha and Dicer expression 
 
Different expression of Drosha and Dicer in osteosarcoma cell line. Osteoblasts were 
used as reference. 
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3.6 Characterization of microRNA 93 and microRNA 210 
Two microRNAs (miR-93 and miR-210) were further characterized for their 
expression, cellular function and physiological role. 
miR-93 belongs to the oncogenic cluster 17-92, a prototypical example of 
polycistronic miRNA gene widely previously described (Introduction, 1.4.2.1). 
MicroRNA 93 is considered as a possible tumoral marker in adult T-cell leukemia 
(Yeung et al., 2008), in gastric cancer (Petrocca et al., 2008) and in ovarian cancer 
(Resnick et al., 2009) but is still poorly described in sarcomas. 
miR-210 is particularly interesting since it localizes on chromosome 11 in a 
region regulated by imprinting mechanisms. Furthermore, it has been recently found a 
link between miR-210 and breast cancer aggressiveness and metastatic capability 
(Foekens et al., 2008). miR-210 is also proposed to have a diagnostic utility in large B-
cell lymphoma (Lawrie, 2008) and to play a crucial role in tumour onset as a key 
regulator of the hypoxia response in epithelial ovarian cancer (Giannakakis et al., 
2008). 
 
Cell lines – The expression of the microRNAs was investigated in various 
tumoral cell lines and in mesenchymal stem cells (MSC) and osteoblasts, as reference 
cells. The analysis of data reported in Figure 3.26, where MSC was the reference, 
showed that miR-210 is generally down-expressed; MG-63 and 143B are quite similar 
to MSC for this microRNA expression (0.83 and 1.24 respectively) whereas Saos-2 
behaviour is like that of the osteoblasts. More heterogeneity was observed for miR-93 
with a maximum of expression for 143B and a minimum for MG-63 and Saos-2, with 
values similar to that found in osteoblasts. 
 
 
 
 
 
 
 
 
 
 
 
3. RESULTS AND DISCUSSION 
 
 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The expression of the two microRNAs is down-regulated in normal osteoblasts 
when compared with the expression in MSC, especially for miR-210. Since osteoblasts 
are the more similar to osteosarcoma cells (Campanacci, 1990), the three 
osteosarcoma cell lines were also compared with osteoblasts for microRNA expression 
(Figure 3.27). miR-93 is confirmed to be over-expressed in 143B. Whereas the analysis 
of microRNA libraries showed miR-210 as present in 143B but not in MG-63 (Table 
3.5), its expression resulted up-regulated in both cell lines in comparison with 
osteoblasts and Saos-2.  
 
 
 
 
 
 
Figure 3.26  MicroRNA 93 and microRNA 210 expression in tumour cell lines 
 
Comparison of different levels of miR-93 and miR-210 in tumour cell lines. Mesenchymal 
Stem Cells (MSC) were used as calibrator. 
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Figure 3.27 MicroRNA 210  and microRNA 93 expression in osteosacoma  cell lines 
 
Comparison of the different levels of miR-210 and miR-93 in osteosarcoma cell lines. 
Osteoblasts were used as reference. 
 
 
As previously reported, the expression of the two enzymes involved in 
microRNA maturation, Drosha and Dicer (Figure 3.25) was found to be lower in 143B 
than in MG-63 and Saos-2. Moreover, the expression of both miR-93 and miR-210 was 
up-regulated in 143B with respect to the other osteosarcoma cell lines. Some 
considerations can be made. For example, the high expression could be related to 
some compensatory mechanisms, or to enzyme specificity for these microRNAs, or to 
a “bias” of the data on enzyme expression resulting from the sampling in a turn-over 
moment. Further investigations need to be performed to clarify this apparent 
discrepancy. The findings on cell lines point out a methodological observation. The 
expression of miR-210 was not found during the library sequencing in 143B. On the 
contrary, the same microRNA resulted up-regulated in this cell line when assayed by 
specific q-PCR. In fact, to consider only some of the longest PCR products for library 
sequencing could be responsible for the loss of some microRNA expression. Moreover 
this loss could be related to unusual conformations of the RNA that may reduce the 
cloning efficiency. 
 
Normal tissues – The expression of the two microRNAs was also investigated in 
normal tissues from different districts (Table 3.6, Figure 3.28 and Figure 3.29) using the 
housekeeping gene U6 as internal control. As expected, the data show wide value 
dispersion in relationship to the specific tissue for both the microRNAs with a higher 
expression of miR-93.  
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Figure 3.28 MicroRNA 93 expression in different tissues 
 
The picture shows the relative expression of each sample not compared with a reference. 
Table 3.6  MicroRNA 93 and microRNA-210 expression in normal tissues 
Tissue U6 miR-93 miR-210 
miR-93 
arbitrary 
expression 
miR-210 
arbitrary 
expression 
Bone marrow 32.07 25.33 29.34 -6.74 -2.73 
Skeletal muscle 26.55 0.96 23.14 -3.89 -3.41 
Heart 23.05 0.88 21.48 -2.40 -1.57 
Stomach 24.27 0.98 23.22 -1.31 -1.05 
Intestin 0.93 0.90 23.59 -0.75 0.10 
Spleen 1.01 20.56 26.23 -3.12 2.55 
Liver 1.00 0.92 24.08 -2.01 0.41 
Pancreas 22.56 20.47 24.10 -2.09 1.54 
Kidney 23.05 0.88 0.97 -2.44 -0.26 
Prostate 1.03 19.12 23.16 -4.86 -0.82 
Lung 0.82 15.21 0.81 -3.73 -0.08 
Frontal Cortex 25.35 18.22 24.89 -7.13 -0.46 
Occipital cortex 27.74 19.32 24.92 -8.42 -2.82 
Fetal brain 19.45 14.25 18.17 -5.20 -1.28 
Fetal eye 0.97 0.80 20.07 -4.13 -2.74 
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Figure 3.29 MicroRNA 210 expression in different tissues 
 
The picture shows the relative expression of each sample not compared with a reference. 
 
Since the supplying firm of analysis kit suggests as good quality samples those 
that present for U6 reference a value in the range 22.5-24.5, the data are also reported 
(Figure 3.30) and analyzed in this context. Both the microRNAs were up-regulated in 
fetal eye tissue; miR-93 was also over-expressed in prostate tissue. miR-210 was 
weakly expressed in spleen and pancreas. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30 MicroRNA 93 and microRNA 210 expression in different tissues 
 
The pictures report only the tissue sample with the same U6 thresold of the heart, considerated 
as a reference for manufactory producer. 
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3.7 Transduction of microRNAs in osteosarcoma cell lines 
The importance of some microRNAs on cell behaviour was investigated on 
143B and MG-63 cell lines after infection or transfection through vectors containing 
miR-93 or miR-7 new (see Mat & Met). 
 
Cell morphology – The infection of 143B cells with, and its consequent over-
expression, was able to change cell morphology, depending on the different efficiency 
in relationship to the clone (Figure 3.31). In particular, the wider changes were 
observed in the 143B miR-7 new 2-3A clone: the cells changed from spindle-shaped to 
coerce. To understand the importance of this different morphology in relation to the 
expression, immunocytochemical (focal adhesion kinases) and molecular (target 
expression) approaches will be carried out.  
 
 
 
 
 
 
 
 
 
Figure 3.31  Morphological change in 143B 
 
The picture shows morphological changes after miR-7 new over-expression. A. 143B wild type; 
B. 143B miR-7 new 2-3A clone. 
 
Proliferation of infected and transfected cell clones – To study the effects of 
miRNAs on cell proliferation, cell clones of 143B and MG-63 infected/transfected with 
miR-93 or miR-7 new were tested. The best growing conditions were previously 
determined for both cell lines using different serum levels (Figure 3.32): previous 
starvation condition (24 hours at 0% serum) and later 10% serum (A); 1% serum (B); 
10% serum (C). A higher proliferation level (about the double in all experimental 
conditions) was observed in 143B osteosarcoma cell line in comparison with MG-63. 
Cell growth was affected by serum content restriction (conditions A and B). For this 
reason, the proliferation assay was carried out at 10% serum condition. 
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Figure 3.32 Kinetics and regression analysis of osteosarcoma cells growth 
 
The panels on the left indicate the kinetics of growth. The right panels describe the regression 
analysis. A. 10% serum after 24 hours of starvation; B. 1% serum; C. 10% serum. 
 
In 143B, the two miR-93 clones showed a proliferation index higher than the 
wild type cells (Figure 3.33A). A similar growth behaviour was displayed by 7 new 2-3A 
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clone, the same already mentioned as the widely modified in cell morphology (Figure 
3.31). The 7 new 2-3B clone proliferation did not significantly differ from the wild type 
one. 
For MG-63 the findings were less clear than for 143B (Figure 3.33B) even if it is 
possible to observe that both the miR-7 new clones seem to proliferate less than the 
wild type MG-63.  
The two tumour lines appear to respond in a different manner to microRNA 
expression. In particular, the over-expression of miR-93 in 143B (1-4A and 1-4B 
clones) induces a proliferation increase whereas the proliferation is not significantly 
modified in MG-63 (B new and DB clones). Considering together these findings with 
the fact that miR-93 is over-expressed in 143B wild type cells, but not in MG-63, 
(Figure 3.27) and the fact that cell proliferation index is about the double in the first 
than in the last cell line (Figure 3.32), specific 143B molecular targets of miR-93 for cell 
replication could be hypothesized. On the other hand, miR-93 over-expression in MG-
63 clones does not significantly alter cell proliferation for a possible lack of specific 
mRNA targets. The identification of these molecules could support our considerations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33  Growth proliferation analysis 
 
Analysis of growth of different clones containing miR-7 new o miR-93 in comparison to wild type 
line. A. 143B; B. MG-63. 
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3.8 Targets of miR-93 and miR-7 new in osteosarcoma cell lines  
Different approaches were carried out to determine the gene expression 
changes after insertion of miR-93 and miR-7 new in 143B and MG-63 cells. 
 
In silico analysis - The identification of putative different genes targets derived 
from the comparison of mRNAs as possible targets of miR-93 found in different 
databases (see Mat & Met) and the presence of the same miR-93-regulated mRNAs 
both in human and mouse genome. For further investigations, four of them were 
chosen in relation to their function in cell physiology:  
• ANK2 - Ankyrin 2 encodes a member of the ankyrin family of proteins 
that link the integral membrane proteins to the underlying spectrin-actin 
cytoskeleton. Ankyrins play key roles in activities such as cell motility, 
activation, proliferation, contact and in the maintenance of specialized 
membrane domains (Hortsch et al., 2002; Le Scouarnec et al., 2008; 
More et al., 2001; Ogawa et al., 2006). 
• ARID4B - AT Rich Interactive Domain 4B (RBP1-like) encodes a protein 
with sequence similarity to retinoblastoma-binding protein-1. The 
encoded protein is a subunit of the histone deacetylase-dependant 
SIN3A transcriptional co-repressor complex, which is involved in several 
cellular processes including proliferation, differentiation, apoptosis, 
oncogenesis, and cell fate determination. The gene product is 
recognized by IgG antibody isolated from a breast cancer patient and 
appears to be a molecular marker associated with a broad range of 
human malignancies (Cui et al., 2004). 
• TXN1P - Thioredoxin Interacting Protein is a new hypoxia marker in 
human microendothelial cells (Le Jan et al., 2006). It interacts with 
reduced thioredoxin modulating the reductive/oxidative cellular state and 
playing a role in stress-induced cellular apoptosis (Chen et al., 2008a; 
Pang et al., 2008). 
• ZNFX1 - Zinc Finger, NFX1-type containing 1 is a new transcription 
factor, not much described in the literature. As previously reported for 
other transcription factor (Romania et al., 2008; Tazawa et al., 2007), it 
could be modulated by microRNAs. 
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q-PCR - These mRNA were investigated on 143B infected (Figure 3.34) and 
MG-63 transfected (Figure 3.35) clones. 
The 143B mir-93 clones were tested (Figure 3.34) for mRNA expression (see 
Mat& Met). The comparison with the wild type points out a similar expression of clone 
mir-93-4A for ANK2 and mir-93-4B for ZNFX1. Very high expression of ARID4B and 
TXN1P was detected in mir-93-4B, whereas the same clone showed down-regulation 
for ANK2. The mir-93-4A clone over-expressed TXN1P and was down regulated for 
ARID4B and ZNFX1. The data, which showed great expression variability in both the 
clones and the genes, did not permit to establish the importance of the four mRNA as 
miR-93 possible targets in this cellular type.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.34 Analysis of candidate genes in 143B miR-93 clones 
 
Graphical representation of arbitrary expression of candidate genes in 143B miR-93 clones in 
comparison with 143B wild type osteosarcoma cells. 
 
The analysis of data on MG-63 cell line (Figure 3.35) showed an “opposite” 
behaviour of the two clones with respect to the wild type: when a gene over-expression 
was present in one clone, a down regulation was found in the other, and viceversa. The 
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over-expression of miR-93 caused a strong down-regulation of TXN1P in MG-63 mir-93 
DB clone, which, on the other hand, showed an overamplification of ANK2, ARID4B 
and ZNFX1. In the MG-63 mir-93 B new clone, whereas high TXN1P expression was 
detected, the microRNA appeared to induce a more or less evident down-expression 
for ANK2, ARID4B and ZNFX1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35 Analysis of candidate genes in MG-63 miR-93 clones 
 
Graphical representation of q-PCR of candidate genes in the different clones transfected with 
miR-93. MG-63 wild type line was used as a reference. 
 
The relevance of miR-93 on the expression of the considered gene appears 
controversial in MG-63 as well as in 143B cell line. The sampling “bias” during a RNA 
turn-over without microRNA 93 expression could explain these results. Further 
investigations, using siRNA and other analysis on more clones, must be performed to 
clearly determine if miR-93 could target these different genes in the same tumour type 
context. 
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Microarray - To understand the involvement of miR-93 and miR-7 new in 
physiological cell pathways, microarray analysis for every microRNA was carried out 
using the total RNA extracted from each stable microRNA clones and wild type cells. 
The RNA quality was determined as described in Mat & Met (Figure 3.36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.36 BioAnalyzer analysis 
 
Graphical representation of RNA test quality of analyzed samples. Every sample shows the two 
peaks typical of ribosomal RNA. 
 
Microarray analysis suggests that both microRNAs could control different gene 
classes (Table 3.8, Table 3.9) pointing out the great relevance of miR-93 and miR-7 
new in cellular pathways.  
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Table 3.8  Candidate target gene of miR-93 
 
Gene number  description  
NM_024833 zinc finger protein 671 (ZNF671), mRNA 
NM_001017372 solute carrier family 27 (fatty acid transporter), member 6 (SLC27A6), mRNA 
NM_080672 phosphatase and actin regulator 3 (PHACTR3), mRNA 
NM_020686 4-aminobutyrate aminotransferase (ABAT), mRNA  
NM_001017424 potassium channel, subfamily K, member 2 (KCNK2), mRNA 
THC2376418 voltage-gated calcium channel alpha(2)delta-3 subunit, (Q8IZS8), mRNA 
NM_016358 iroquois homeobox protein 4 (IRX4), mRNA 
NM_014867 kelch repeat and BTB (POZ) domain containing 11 (KBTBD11), mRNA 
NM_014839 plasticity related gene 1 (LPPR4), mRNA 
THC2311329 Hexaribonucleotide binding protein 3 (Q8VI61), mRNA 
NM_182898 cAMP responsive element binding protein 5 (CREB5), mRNA 
NM_006472 thioredoxin interacting protein (TXN1P), mRNA 
NM_006125 Rho GTPase activating protein 6 (ARHGAP6), mRNA 
 
 
Table 3.9  Candidate target gene of miR-210 
 
Gene number  description  
NM_001003395 tumor protein D-52-like1 (TPD52L), mRNA 
NM_016358 iroquois homeobox protein 4 (IRX4), mRNA 
NM_001546 inhibitor of DNA binding 4 (ID4), mRNA 
NM_024016 homeobox B8 (HOXB8), mRNA 
NM_017943 F-box protein 34 (FBXO34), mRNA 
NM_004613 transglutaminase 2 (TGM2), mRNA 
NM_183045 ring finger protein (C3H2C3 type) 6 (RNF6), mRNA 
NM_002609 platelet-derived growth factor receptor (PDGFRB), mRNA 
NM_198974 protein tyrosine kinase 9 (PTK9), mRNA 
 
 
 
The data obtained with microarray permit to identify a lot of genes down 
regulated by the miR-93. TXN1P, a gene previously assayed by q-PCR in the two 
osteosarcoma cell lines 143B and MG63, appears within these targets. The PCR assay 
detected a down-regulation only in MG63 mir-93 DB clone but not in 143B clones. 
These findings suggest that miR-93 could act with a cell type-dependent specificity.  
The two microRNAs seem to control specific gene targets (Figure 3.37). In 
particular, miR-93 appears to interact with genes relative to “ion channels” and 
“transporters” and miR-7 new with those relative to “receptors” and “oncogenes/tumour 
suppressors (OG/TS)”. Further investigations are needed to unravel the role of these 
microRNAs inside the cell. 
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Figure 3.37 Microarray results 
 
Graphical representation of different classes of regulatory gene probably modulated by A. miR-
93 and B. miR-7 new. 
 
Detection of functional mRNA targets - The new method published by Vatolin 
and colleagues (Vatolin et al., 2006) was applied to identify the targets of miR-93. The 
data obtained by comparison with Blast database showed that all the amplified 
sequences of the purified fragments always aligned with mRNA of Tat, a protein 
involved in Acquired Immune Deficency Syndrome (AIDS), independently from their 
length. These data suggest that miR-93 inside osteosarcoma cells has only a target 
gene. These results are unexpected because it is known that microRNA normally 
regulates the expression of hundreds of target genes. A possible reason for these 
findings could be due to the tight parameters used for PCR: in this way not only the 
seed region but a large portion of or the whole microRNA fully paired with a 
complementary no-target mRNA. 
To unravel the question, new experiments with weaker PCR condition have to 
be carried out. 
 
3.9 Towards the development of a new intravital microscopy assay for the 
analysis of lymphatic intravasation 
Lymphatic invasion of tumour cells is a fundamental step in the metastatic 
process, but little is known about the mechanism of this phenomenon and the factors 
that may control it. Although several intravital microscopy systems are available for the 
real-time assessment of haematic extravasation no system is currently available for the 
analysis of lymphatic intravasation. In the effort to provide such system, an intravital 
microscopy approach was exploited in collaboration with the group of Prof. Daniela 
Negrini (Dipartimento Scienze Biomediche Sperimentali e Cliniche – Università degli 
Studi dell’Insubria, Varese – Italy). The technique allows to monitor cell capability to 
A B 
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spontaneously invade the lymphatic vessels of rat pleural diaphragmatic cavity 
(Cahalan et al., 2002). A first experiment was carried out using syngenic osteosarcoma 
cell line UMR-106 to avoid the immunological complications due to species differences 
between human and rat tumour cell lines. Diaphragm and lung were observed after two 
different times (24h and 30h) since sarcoma cell injection (Figure 3.38). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38 UMR-106 
 
Diaphragm (left) and lung (right) analysis after UMR-106 injection. 
 
As shown in Figure 3.38, the presence of sarcoma cells in the lung, but not in 
the diaphragm, after only 24 hours following cell inoculation, suggested that the cells 
crossed the diaphragm lymphatic vessels very quickly. Although care was taken to 
avoid to insert cells directly in to the lungs, this possibility could not entirely be 
excluded and the consistency of the results at different time intervals also suggested 
that this error was not likely. 
To confirm the great capability of tumour cells to quickly spread through 
lymphatic vessels, the monitoring of injected gliosarcoma cells (C6), known as highly 
aggressive cells (Dexter et al., 1983), was also performed at shorter time (12 hours) in 
diaphragm (Figure 3.39) of other animals. Whereas it was possible to note the 
presence of tumour cells in the diaphragm at 12 hour post cell injection, the images 
after 24 and 48 hours suggested cell migration from diaphragm.  
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Figure 3.39 C6 
 
Different time of analysis of different diaphragms Only into 12 hours after injection of C6 
tumoural cells, the cells are detectable in the diaphragm. 
 
These first results hinted to a quick spreading of tumoral cells using a 
diaphragmatic lymphatic loop able to supply a low-resistance pathway for fluid (and 
probably cell) drainage from the serous cavities (Moriondo et al., 2008). 
To further demonstrate the applicability of the above intravital microscopy assay 
to monitor the tumour cell aggressiveness and their ability to invade lymphatic vessels, 
another experiment was carried out (Figure 3.40) using murine melanoma cells (B16) 
stably transfected with vector (B16-mock) or a vector containing NG2 proteoglycan 
(B16-NG2). B16 is a very aggressive cell line (Dexter et al., 1983; Maiorana et al., 
1992), NG-2 is a membrane proteoglycan involved in cell motility (Burg et al., 1998; 
Burg et al., 1997; Eisenmann et al., 1999; Fang et al., 1999) and in cellular responses 
to growth factors (Goretzki et al., 1999; Grako et al., 1999; Grako and Stallcup, 1995; 
Nishiyama et al., 1996) that could alter cell spreading efficiency. After 12 hours from 
injection (Figure 3.23A) only B16-mock were still present inside the diaphragmatic wall 
whereas the B16 clone with stable expression of NG2 was less detectable in this area. 
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In 24 hour-samples (Figure 3.40B), green melanoma cells were not found in any of the 
two models. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.40 B16 
 
B16-NG2 cells seem to be already poorly present in diaphragm after 12 hours of injection. 
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Thus NG2 over-expression seemed to increase the spreading of tumour cells 
through the lymphatic vessels, recently emphasized as an exclusive stream for 
metastasis formation (Azzali, 2007), suggesting a putative role of NG2 in this process. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
4. CONCLUSIONS 
 
 
93 
The importance of small RNAs in the control of biological processes is rapidly 
increasing (Aboobaker et al., 2005; Abrahante et al., 2003; Alvarez-Garcia and Miska, 
2005; Chang et al., 2004; Chen et al., 2004; Fazi et al., 2005; Giraldez et al., 2006; 
Grosshans et al., 2005; Hornstein et al., 2005; Johnston and Hobert, 2003; Lin et al., 
2003; Naguibneva et al., 2006; Poy et al., 2004; Schratt et al., 2006; Sokol and 
Ambros, 2005; Wienholds et al., 2005; Zhao et al., 2005). In particular microRNAs have 
been described as potential biomarkers in different diseases (Calin et al., 2005; 
Foekens et al., 2008; Huang et al., 2008; Ma et al., 2007; Schetter et al., 2008; 
Takamizawa et al., 2004; Tavazoie et al., 2008) because their over- or down- 
regulation may modulate the expression of important cellular factors involved in 
metabolism, apoptosis and cancer. 
 Four microRNAs, found to be up regulated in three osteosarcoma cell 
lines were further analyzed in surgical samples of low and high grade osteosarcoma 
patients. miR-484 in both osteosarcoma grade was down regulated and has the 
potential of being a marker of these diseases. In high grade osteosarcoma another 
microRNA, miR-183, was similarly down regulated. miR-484 and miR-183 together, 
could be putative biomarkers of high grade osteosarcoma and a wider number of cases 
is now under examination to establish a possible prognostic significance of this 
differential microRNA expression. 
 In a transendothelial migration assay using HUVEC cells, the three 
osteosarcoma cell lines showed a distinct migration capability, different from that of 
other tumour cell lines tested. In particular Saos-2 and MG-63 cells showed the same 
behaviour, whereas 143B cells crossed the endothelial layer more slowly than the other 
two osteosarcoma lines. Moreover, 143B grew faster than MG-63. Using other 
endothelial systems, for example lymphatic endothelial cells monolayer, for 
transmigration assay may produce different results.  
 Two microRNA libraries were created using RNAs from 143B and MG-
63 osteosarcoma cell lines. microRNA sequencing allowed the identification of an 
unknown sequence, named miR-7 new, localized on chromosome 7 that shows the 
characteristic of a putative microRNA. Some microRNAs described in the databases 
were identified in both the two lines. Some other, for example miR-210, seemed to be 
characteristic of one of the two cell lines. Otherwise, the more careful analysis with 
qRT-PCR identified the presence of miR-210 in both cell types. This finding points out 
a methodological observation: to consider only some of the longest PCR products for 
library sequencing could be responsible for the loss of some microRNA expression. 
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Moreover this loss could be related to unusual conformations assumed by RNA that 
may reduce the cloning efficiency. 
 The presence of two microRNAs, miR-93 and miR-210, was detected 
both in various tumoral cell lines and normal tissues. A specific expression was found 
in relation to the different cell lines and tissues. In particular miR-93 is over-expressed 
in 143B cell line and in brain tissues. 
 Several approaches (infection/tranfection, in silico analysis, qRT-PCR, 
DNA microarrays) have been undertaken to determine the importance of miR-93 and 
miR-7 new in biological and molecular pathways. miR-7 new seemed to be involved in 
the control of cell morphology. Studies are in progress to understand their gene targets. 
 To be able to address the possible role of microRNA in the control of 
metastasis formation and in particular the steps entailing entrance of the cells into the 
lymphatic circuits, an effort was made to devise a new intravital microscopy approach. 
Cells of several tumour types with different aggressiveness were used to define the 
usefulness of this system. The system seemed to be able to define times, factors and 
molecules potentially involved in the lymphatic intravasation process. 
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